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Abstract
As the presence of hypervirulent Klebsiella pneumoniae (hvKP) has not been studied
in the United Arab Emirates (UAE), the aim was to determine its rate among
bloodstream isolates collected in a tertiary care hospital during a two-year period. K.
pneumoniae blood isolates of 125 individual patients from Tawam Hospital, Al Ain in
2014-2015 were investigated. Clinical data on patients’ demographics and underlying
medical conditions were collected. Speciation was carried out by VITEK 2,
antimicrobial susceptibility was determined by disc diffusion and for colistin by
microdilution. Hypermucoviscosity was assessed by string test. Genetic markers of
hypervirulence (iucA, rmpA, rmpA2), K1 and K2 serotype-specific alleles, and
carbapenemase genes were detected by PCR. HvKP isolates were compared by PFGE
and by MLST and the localisation of rmpA was confirmed by hybridization. Fischer’s
exact test was used to calculate correlations between categorical variables. Of the 125
isolates 13 (10.4%) iucA and rmpA/rmpA2 positive strains were identified and were
considered hvKP. Eight of them were string test positive. They were distributed among
CC23 - serotype K1 (6, PFGE similarity >80%), ST65 – K2 (1), ST380 – K2 (2), ST86
– K2 (1), ST36 (1) and ST714 (2), respectively. While the majority of them were
susceptible to most antibiotics tested, one K. pneumoniae ST23 was multi-drug
resistant and produced a new allele of VIM carbapenemase. hvKP strains were more
likely to be isolated from diabetic than from non-diabetic patients (P=0.001) and from
patients who have not received prior antimicrobial therapy (P=0.0208). A further 11
iucA positive isolates were rmpA/rmpA2 and string test negative. Ten of these strains
produced OXA-232 carbapenemase and were extremely drug resistant (XDR). These
isolates belonged to K. pneumoniae ST231. The results surmise that while members
of this latter, carbapenem resistant group may not fully qualify as hvKP, yet, they carry
the potential to develop into hvKP by acquiring the plasmid-coded exopolysaccharide
synthesis regulator, rmpA. An alarming rate (>10%) of hvKP was demonstrated among
bloodstream isolates studied with the presence of a carbapenem resistant, hyperviscous
phenotype hvKP ST23 isolate producing a novel VIM-carbapenemase.
Keywords: Hypervirulent Klebsiella pneumoniae (hvKP), Hypermucoviscosity,
String test, Virulence factors, Carbapenemase genes, Enterobacteriaceae.
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)Title and Abstract (in Arabic

دراسة سالالت الكلبسية الرئوية الضارية المعزولة من مجرى الدم في االمارات العربية
المتحدة
الملخص

نظرا لعدم وجود دراسات كافية لسالالت بكتيريا الكلبسية الرئوية الضارية ) (hvKPشديدة
ً
الضراوة في دولة اإلمارات العربية المتحدة ،كان الهدف هو تحديد معدالته بين العينات المعزولة
من مجرى الدم التي تم جمعها في مستشفى قطاع الصحة الثالث خالل فترة عامين.
ضا في
تم فحص ما يعادل  125عينة من بكتيريا االلتهاب الرئوي المعزولة من  125مري ً
مستشفى توام ،العين في الفترة ما بين  .2015-2014تم جمع البيانات السريرية والحاالت الطبية
األساسية للمرضى .تم تعريف البكتيريا عن طريق ال  ،VITEK 2وتم تحديد القابلية للمضادات
الحيوية عن طريق ال  ،disc diffusionاما بالنسبة لمضاد الكوليستين فتم اختباره عن طريق
التخفيف الجزئي .تم تقييم فرط المخاطية عن طريق اختبارال ( .)Stringتم الكشف عن عالمات
جينية لتحديد مدى ضراوة العينات ) ،(iucA, rmpA, rmpA2تم تعيين ال  K1و  K2الخاصة
بالنمط المصلي ،وكذلك جينات ال  carbapenemasesبواسطة ال  .PCRتمت مقارنة عينات
ال  hvKPبواسطة تقنية ال  PFGEو  ،MLSTتم تحديد وجود جين ال  rmpAبواسطة ال
 .hybridizationتم استخدام اختبار فيشر الدقيق لحساب االرتباطات بين المتغيرات الفئوية
للفئات المختلفه.
بناء على دراسة ال  125عينة ،تم ايجاد  )%10.4( 13عينة موجبة لجينات ( iucA,
 )rmpA/rmpA2واعتبرت عينات شديدة الضراوة ( .)hvKPثمانية منهم كانت ايجابية الختبار
ال ( )stringوتم توزيعها بين االنماط التالية CC23 - K1 (6), ST65 - K2 (1), ST380
) - K2 (2), ST86 - K2 (1), ST36 (1) ST714 (2على التوالي .على الرغم من أن معظم
عينات ال ( )hvKPكانوا شديدي الحساسية لمعظم المضادات الحيوية التي تم اختبارها ،إال أن
أحد أنواع هذه البكتيريا المنتمية لنمط ال  ST23كان مقاو ًما لعدة مضادات وأنتج نوعا جديدًا من
جين ال ( .)VIMتم عزل سالالت ال  hvKPأكثر من مرض السكري مقارنةً بالمرضى غير
المصابين بالسكري ( )P=0.001وكذلك من المرضى الذين لم يتلقوا اي عالج سابق بالمضادات
الحيوية (.)P=0.0208
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كذلك بينت الدراسات ان هناك  11عينة موجبة لجين ال  iucAولكنها سالبة لكل من جينات
ال ( )rmpA/rmpA2وكذلك الختبارال ( .)stringأنتجت عشر من هذه السالالت جين ال
OXA-232وكانت مقاومة للغاية لألدوية ( .)XDRتنتمي هذه العينات إلى الكلبسيه الرئوية من
النمط  ،ST231و نحن نفترض أنه على الرغم من أن أعضاء هذه المجموعة األخيرة ،مجموعة
ال  OXA-232المقاومة للكاربابينم قد ال ينتمون الى الساللة الضارية  hvKPشديدة الضراوة،
إال أنهم يحملون القدرة على التطور إلى هذه الساللة من خالل الحصول على جين ال rmpA
المنقول بواسطة البالزميدات.
تم إثبات وجود معدل ينذر بالخطر ) (>10%من السالالت الضارية الشديدة الضراوه
( )hvKPبين العينات المعزولة من مجرى الدم التي تمت دراستها مع وجود عينة للنمط ST23
المقاوم للكاربابينيم ،والمنتج لنوع جديد من جين ال .VIM
مفاهيم البحث الرئيسية :بكتيريا الكلبسية الرئوية الضارية ) ،(hvKPفرط المخاطية ،اختبارال
( ،)Stringمضادات الحيوية ،عالمات جينية ،جينات ال  ،Carbapenemasesكاربابينيم.
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Chapter 1: Introduction
1.1 Enterobacteriaceae
The Enterobacteriaceae family is the largest heterogeneous group of medically
important Gram-negative bacteria. Currently it contains 50 genera and dozens of
named species as well as subspecies. Initially, they were classified according to their
biochemical properties, antigenic structure and subsequently by DNA-DNA
hybridization and 16S rRNA gene sequencing. Most members of the family are
ubiquitous organisms besides their human and animal hosts as part of the normal flora,
are also found in soil and water (Murray, 2013).
They are Gram-negative, non-spore straight rods relatively small in size (0.3
to 0.3 to 1.0 x 1.0 to 6.0 μm). Some genera are motile by means of peritrichous flagella,
meanwhile others are non-motile (Murray, 2013).
Members

of

Enterobacteriaceae

family

exhibit

varying

levels

of

pathogenicity. Those that are members of the normal flora can cause infections only if
displaced to other body-sites (e.g. Escherichia coli from the gut to the urinary tract).
Others are strict pathogens, like members of the Salmonella genus, while several of
them cause mainly opportunistic infections, i.e. exclusively in patients with
compromised defense systems (e.g. Serratia marcescens). The subject of the thesis is
an important member of this family belonging to the genus Klebsiella, i.e. K.
pneumoniae (Murray, 2013).
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1.2 The genus Klebsiella and Klebsiella pneumoniae
The intensive recent research directed towards the genus Klebsiella has
resulted in considerable fluidity in its taxonomy that is far from a complete consensus.
According to the Taxonomy Browser of the NCBI the genus contains several species
and subspecies of which the most important ones are K. pneumoniae, K. oxytoca, K.
rhinoscleromatis, K. quasipneumoniae, and K. variicola (Wyres and Holt, 2016). K.
pneumoniae are fermentive bacteria which produce lysine decarboxylase but not
ornithine decarboxylase and are generally positive in the Voges-Proskauer test
(Enjalbert et al., 1979). They are non-motile, facultative anaerobes and it can grow
rapidly on variety of selective and non-selective media. The colony appearance on the
media is typically large, mucoid (wet, heaped, viscous colonies) due to a prominent
capsule (Murray, 2013; Podschun and Ullmann, 1998).
It was first described by the German microbiologist Edwin Klebs (1834 – 1913)
in 1875 while examining the airways of patients who died due to pneumonia.
Eventually, the species was formally described by Carl Friedlander in 1882 and the
organism was named "Klebsiella pneumoniae" by Trevisan in 1885 (Etymologia:
Klebsiella et al., 2010) (Friedländer, 1882). To honor Friedlander’s contribution, the
multilobar bronchopneumonia often leading to pulmonary abscesses and lung
necrosis, typically seen in cases caused by K. pneumoniae used to be called
“Friedlander pneumonia”. Currently, K. pneumonia is one of the important causes of
human morbidity and mortality (Wyres and Holt, 2016).
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1.3 The pathogenicity of Klebsiella pneumoniae
K. pneumoniae is responsible for numerous infections within hospitals, long
term care facilities as well as in the communities worldwide and (Carpenter, 1990). It
is often described as an opportunistic pathogen as, nowadays, most infections are seen
in hospitals among inpatients with varying degrees of immunocompromisation. It
should be kept in mind, however, that although it is part of the normal flora, under
certain circumstances, they have the ability to cause severe illnesses, such as
pneumoniae

or

bacteremia,

meningitis

and

other

infections

immunocompromised people, as well (Figure 1) (Murray, 2013).

Figure 1: Sites of infections (Murray, 2013)

in

non-
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Klebsiella spp. are ubiquitous in nature, in environments, such as in water,
sewage, soil and plants (Morrow et al., 1978; Wyres and Holt, 2018). In addition to
the hospital settings and medical devices, in association with the human host, K.
pneumoniae is usually found in the mouth, skin and intestines. Generally, the
colonization of the GI tract by K. pneumoniae takes place before the development of
nosocomial infections (Podschun and Ullmann, 1998). It has been found that K.
pneumoniae biofilms that appear on medical devices (e.g., catheters and endotracheal
tubes) plays a significant role in infection of catheterized patients (Schroll et al., 2010).
Studies by Jagnow and Clegg (2003) showed that nosocomial infections caused by K.
pneumoniae have the tendency to be persistent due to the presence of K. pneumoniae
biofilms in-vivo which protects the bacteria from attacks of the host immune responses
and from antibiotics (Jagnow and Clegg, 2003). In addition, nosocomial isolates of K.
pneumoniae often exhibit multidrug-resistance (Paterson et al., 2004; Munoz-Price et
al., 2013). Such resistance factors considerably increase the ability of these organisms
to spread widely and rapidly which will often lead to nosocomial outbreaks within the
hospital, making it one of the most common organisms causing such epidemics (Kuhn
et al., 1993).
Taken together, K. pneumoniae is a globally encountered pathogen that
remains a significant cause of both community-acquired and healthcare-associated
infections, including bacteremia. Currently, with the increase of hospitalized and
immunocompromised patients, most infections are encountered nosocomially among
individuals suffering from various underlying conditions (Shon et al., 2013).
There are two major factors that make K. pneumoniae one of the most
important pathogens of recent times:
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its broad pathogenic potential and



its proclivity to become resistant to antibiotics.

1.3.1 Virulence factors
The disease-causing capacity of an organism, in relation to a specific host, is
called “pathogenicity”, while, its quantitative expression is called “virulence”. Both
terms refer to the capacity of a microorganism to replicate and disseminate and cause
disease or kill the host. Virulence factors are molecules and cells structure components
with functions essential in the pathogen–host interaction during the process of
infection. These traits enhance the ability of bacteria to cause pathological changes
within the host (Baer and Harold, 1956; Murray, 2013; Clegg et al., 1992; Rosen et
al., 2008).
K. pneumoniae exhibit complex interactions with the host, and hence, a number
of bacterial factors have been identified that contribute to the pathogenesis of these
infections Figure 2 and Table 1.

Figure 2: Pathogenicity factors of Klebsiella (Ottow, 1975)
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Table 1: Virulence factors involved in the pathogenesis of Klebsiella pneumoniae
(Clegg and Murphy, 2016)
Factor
Capsule
LPS
Siderophore
Urease
Type 1 fimbriae
Type 3 fimbriae
Biofilm
formation
Antibiotic
resistance

Function
Inhibit and evade phagocytosis by host cells, induces dendritic
cell maturation, neutralizes antibacterial activity of host
defense
O antigen provides serum resistance
Scavenge essential iron for survival, hypermucoviscous
phenotypes have been linked to increased iron-binding activity
Limited role in precipitation of inorganic salts leading to
catheter encrustation
Involved in the formation of intracellular bacterial
communities
Important for biofilm formation on biotic and abiotic surfaces,
role in biofilm formation on urinary catheters in vivo remains
to be elucidated
Formation promotes resistance to host killing and
antimicrobials, experimentally shown to be facilitated in part
by fimbriae and capsule
Carbapenem-resistance prevents many treatment options

1.3.1.1 Capsular antigens
Two major components are expressed on the surface that are essential for the
virulence of K. pneumoniae: the capsular polysaccharide (CPS; the K antigen) and the
lipopolysaccharide (LPS; the O antigen) (Follador et al., 2016) K. pneumoniae
contains a thick capsule layer surrounding the bacterium (160 nm) that is generally
considered an important factor in its pathogenicity (Figure 3).
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Figure 3: Cell wall structure of Enterobacteriaceae (Murray, 2013)
For a bacterium to cause infections, the first step is to enter and colonize the
host and in this the capsule plays important roles. The capsular material forms a thick
bundle of fibrillous structures that covers the bacterial surface. The capsule is strongly
antiphagocytic, protecting the bacteria from phagocytosis and from bactericidal serum
factors. Furthermore, it can act as a barrier to toxic hydrophobic molecules, like
detergents (Murray, 2013).
Strains of K. pneumoniae can express several antigenically distinct capsules
and some are considered to be associated with increased virulence potential. The
capsule antigens K1, K2, K4 and K5 are mainly associated with high virulence degree
(Kato, 1983). The degree of virulence conferred by a particular K antigen might be
connected to the expression of type 1 fimbriae (a mannose receptor-specific adhesin)
(Podschun and Ullmann, 1992; Ohman, 1993).
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The genes responsible for the production of capsules by K. pneumoniae were
originally designated as cps gene cluster and were mapped close to his on the bacterial
chromosome (Clegg and Murphy, 2016). It has been discovered by cloning of the cps
cluster that the genes are approximately 15kb of DNA and has all the determinants
which are necessary to define the serotype of a strain (Clegg and Murphy, 2016). The
studies showed that three alleles of a different gene named rmpA/A2 have been
described to play a role in the activation of cps-gene expression (Cheng et al., 2010;
Lai et al., 2003).
The alleles vary between serotypes and the geographic region of the isolates.
Two of the alleles are plasmid encoded and the third one is chromosomal. Over
production of rmpA leads to a hypermucous phenotype in K. pneumoniae and to the
increase in expression of the transcriptional fusions of cps-promoter regions (Lai et
al., 2003). The transcription of rmpA is inhibited by not only the Fur protein but also
by other genes associated with iron-acquisition systems in K. pneumoniae (Lin et al.,
2011). For that reason, the concentration of available iron in the environment of the
Klebsiella strains can play a major role in the expression of the virulence gene,
including the amount of capsule produced by clinical isolates. The studies showed that
K1 serotypes of K. pneumoniae are associated with causing severe disseminated
infections. The mucoviscosity-associated gene (magA) was found to be part of the cpsgene cluster in these isolates and necessary for K1 biosynthesis (Fang et al., 2010).
Earlier, this gene has been used to identify, by polymerase chain reaction (PCR), K1positive strains, but recently a similar allele was found in other K-serotypes (Fang et
al., 2010).
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The wzy and wzi genes are present in all K types, but each one of them has a
high level of variable sequence between distinct K types. Based on that, wzy-targeting
PCR assays have been set to identify K1, K2, K3, K5, K20, K54 and K57 (Turton et
al., 2010; Fevre et al., 2011), and by wzi sequencing one can reveal the K types of
most clinical K. pneumoniae isolates (Brisse et al., 2013).
Generally, the most virulent strains of K. pneumoniae produce a capsule made
of saccharides that do not facilitate binding to phagocytic cells and hence are more
resistant to phagocytosis (Clegg and Murphy, 2016).
1.3.1.2 Lipopolysaccharide (LPS)
Similarly to other members of the family Enterobacteriaceae, the
lipopolysaccharides (LPSs) of K. pneumoniae consist of three structural domains
shown on Figure 3, (i) the hydrophobic lipid A, which is a major component of the
outer leaflet of the Gram-negative outer membrane and is responsible for the endotoxin
activity and is an important virulence factor, (ii) the core oligosaccharide, which is
linked to lipid A and provides the attachment site for (iii) the long chain polysaccharide
(O antigen; O chain) (Follador et al., 2016; Murray, 2013).
Beyond the endotoxic nature of LPS, the O antigen also contributes
significantly to the virulence of K. pneumoniae. The presence of cell wall receptors
enables K. pneumoniae to attach to the host cell. Correspondingly, LPS have been
implicated in the pathogenesis of K. pneumoniae causing community-acquired
pyogenic liver abscess (PLA) (Tomas et al., 1997).
It has been shown in different studies that K. pneumoniae O-antigen prevents the
access of complement components to activators (e.g., porins and rough LPS) and hence
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contributes to bacterial resistance against complement-mediated killing (Merino et al.,
2000).
1.3.1.3 Pili (fimbriae) and adhesion
Pili or fimbriae are hairlike structures, 10 μm long and have a diameter of 1 to
11 nm (Jones and Isaacson, 1983). They are composed of polymeric globular protein
subunits (pilin) and are protruding from the surface of the bacteria (Murray, 2013). As
an adherence factor, fimbriae are important determinant of colonization.
The three K. pneumoniae fimbrial adhesins that have been described in detail
are types 1 and 3 fimbriae and the Kpc fimbriae (Clegg et al., 2011; Wu et al., 2010).
Type 1 fimbriae, also known as mannose-sensitive fimbriae, because of their capability
to bind soluble mannose as a competitive inhibitor to binding, are usually encoded by
the fim gene cluster. Type 3 fimbriae are encoded by the mrk-gene cluster and can be
present in K. pneumoniae on a plasmid and/or a chromosomal gene cluster (Clegg and
Murphy, 2016). It has been noted that mrkA is the major structural component of the
fimbrial shaft and that mrkD helps to facilitate binding to extracellular- matrix proteins
and act as the fimbrial adhesion (Clegg and Murphy, 2016).
The studies showed that the Kpc fimbriae are most frequently associated with
K1-positive strains of K. pneumoniae causing disseminated pyogenic infections (Wu
et al., 2010). The production of these fimbriae is mediated by the kpcABCD gene
cluster, although the conditions for optimal expression of these genes have not been
yet fully understood.

11
The other type of Klebsiella spp. adhesin is the plasmid encoded CF29K. This
fimbrial type is characterized by aggregative adhesion to the intestinal cell lines (Joly,
1992).
1.3.1.4 Serum resistance
The bactericidal effect of serum is one of the first line of defense by the host
against invading microorganism. Serum resistance represented by activation of
complement proteins. Complement components are activated in a cascade manner
through 3 different pathways of activation namely classical, alternative or by the lectin
pathway. The complement system plays a vital role in humoral defense against
microbial pathogens. The serum bactericidal system has a very important role which
is to prevent microorganisms from invading and persisting in the blood (Ramm et al.,
1983; Taylor, 1983; Old and Adegbola, 1985; Doorduijn et al., 2016). In a study of
Gharrah et al., 2017 serum resistance was one of the pathogenicity factors of Klebsiella
and serum resistance was an indication of the higher pathogenicity (Gharrah et al.,
2017). Interestingly, studies found relationship between ESBL production and serum
resistance showing that serum resistance was elevated in K. pneumoniae ESBL
producer than non-ESBL producing K. pneumoniae (Lin et al., 2016).
1.3.1.5 Iron acquisition
Iron is an essential factor in bacterial growth but the availability of free ferric
iron (Fe3+) in the host is usually extremely low. Consequently, pathogens, such as K.
pneumoniae should be equipped to secure their iron supply from the host. This is
achieved by a variety of mechanisms, most commonly either through ABC transporters
and/or by secreting low-molecular-weight, high-affinity iron chelators, called
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siderophores (Bullen et al., 1978; Khimji and Miles, 1978; Griffiths, 1988; Behnsen
and Raffatellu. 2016; Ellermann and Arthur, 2017).

Although the presence of

siderophores are likely to be essential in all systemic infections, their role was mostly
studied in a set of K. pneumoniae strains, called hypervirulent K. pneumoniae.
Approximately a dozen different systems have been identified that play a role
in supplying iron to K. pneumoniae (Liu et al., 2014) of which the siderophore-based
systems are the most important (Table 2).
Table 2: The most common iron acquisition systems of K. pneumoniae (simplified
from Liu et al., 2018)
System
Kfu

Name
ABC transporter

Fep-Ent

Enterochelin

IroA
Iuc

Salmochelin
Aerobactin

High-pathogenicity island Yersiniabactin

Genes
kfuABC
fepA-entD,
fes-entF,
fepDGC, ybdA, febB,
entCEBA
iroN, iroBCDN
iucABCD-iutA
ybtPQXS, YbtA-irp2-irp1ybtUTE-fyuA

In clinical isolates these siderophore genes can be present in different
combinations. Mutants lacking them are attenuated (Clegg and Murphy, 2016). A
study of more than thirty strains of 23 different serotypes of K. pneumoniae showed
that the siderophore enterochelin was the predominant iron-salvaging-system
compound produced in urinary tract infections (Tarkkanen et al., 1992). This was in
contrast to bacteremic strains, mainly K1 and K2 serotypes, in which aerobactin was
correlated to virulence. Some, particularly the aerobactin system is highly
characteristic to strains with increased virulence (see later).
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1.3.2 Hypervirulent (Hypermucoviscous) Klebsiella pneumoniae
Lately, the majority of infections caused by ‘classic’ K. pneumoniae (cKP)
occurred in hospitals and long-term care facilities. Recently, however, a new type of
infection emerged caused by more or a less distinct group of strains, initially called
hypermucovicous, lately named hypervirulent K. pneumoniae (hvKP). Often, these
infections were community-acquired, invasive, life-threatening ones; not infrequently
with unusual locations among young, otherwise healthy individuals, i.e. showing a
real, instead of opportunistic pathogenic potential of the species. The first cases were
recorded in the Asian Pacific Rim including Taiwan, Korea, Vietnam and Japan. In
the mid-1980s and 1990s, Taiwan has recorded patients with no previous history of
hepatobiliary disease presenting with community-acquired pyogenic liver abscesses
(CA-PLA) (Cheng et al., 1991; Wang et al., 1998; Lin et al., 2018). The hvKP
infections were seen in all age groups and despite the fact that some patients have comorbidities, it is commonly noted in younger and healthy patients and as a result, hvKP
will cause infection in various sites in the body such as abdominal disease, splenic
abscess, thoracic disease (pneumonia), meningitis and other CNS infections, UTI and
bacteremia.
1.3.2.1 Hypermucoviscous Klebsiella pneumoniae
Most hvKP, when growing on blood agar (BA), appear to have excess amount
of mucus, even more than the regular amount causing “mucoid” appearance of the
colonies of the species, i.e. these colonies are hypermucoviscous. Such strains can be
identified by the ‘string test’. The formation of a viscous string of > 5 mm in length
using inoculation loop and stretching the bacterial colonies is considered positive as
shown in Figure 4 (Shon et al., 2013).
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Figure 4: Positive ‘string test’ on a hypervirulent strain of Klebsiella pneumoniae
(Shon et al., 2013)

1.3.2.2 Hypervirulent Klebsiella pneumoniae
Several genes have been implicated to contribute to the virulence of K.
pneumoniae, like those associated with iron uptake (e.g. iucA, iutA, ybtS, entB, kfuB),
fimbria formation (e.g. fimH, mrkD) and in particular the formation and
hyperproduction of capsule (e.g. magA, wabG, wcaG, rmpA, rmpA2) (Fang et al.,
2007; Turton et al., 2010; Candan and Aksoz, 2015). While it is still debated what are
the clear criteria of hypervirulence, there are certain factors that show a close
association with it.
As the initial marker of hypervirulence was linked to the highly viscous
character of the strains, extensive studies were performed to identify the capsular
serotypes playing unique role in facilitating it. There are nearly 80 capsular serotypes
including K1, K2, K5, K16, K20, K54, K57 which were implicated to facilitate
virulence in hvKP strains (Chuang et al., 2006; Pan et al., 2008; Cheng et al., 2012).
Of the different capsular serotypes, particularly K1 and K2 were the most commonly
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encountered among hvKp. In one study, among the 67 K. pneumoniae that were
isolated from the community in Canada, Denmark, Norway, South Africa, Taiwan and
the United States in the period of 1996 to 2012 as 30 strains appeared to be hvKP by
being hypermucoviscous. The majority (28/30) belonged to K1 capsule serotype and
the other two belonged to K2 (Cheng et al., 2012). In another study in China 230 strains
were isolates from pneumonia, intra-abdominal infection and bloodstream infections.
37.8% of the isolates were hvKP, out of which, 33.3% were K1 and 17.2% were K2
(Wang et al., 2016).
In a separate project (Yinjuan, 2017), a total of 84 hyperviscous isolates were
tested for the capsular antigen and the following were identified: K1 (23.8%, 20/84),
K2 (42.9%, 36/84), K5 (2.4%, 2/84), K20 (4.8%, 4/84) and K57 (9.6%, 8/84). In
Singapore and Taiwan also capsular serotypes K1 and K2 dominated isolates of K.
pneumoniae causing liver abscess. A total of 73 isolates were serotyped and the most
predominant serotype K1 accounting for (34/73; 46.6%), K2 (15/73; 20.5%) and nonK1/K2 (24/73; 32.9%) (Yeh et al., 2007). Through their attempt to investigate gene
association with capsular serotype it was found that magA was restricted to, and
present in all 34 K1 isolates, while all the 73 hyperviscous isolates were positive for
rmpA (Yeh et al., 2007). Severe complications of hvKP bacteremia is common. In a
Chinese study (Yeh et al., 2010; Hsu et al., 2011). Studying 285 blood culture isolates
the hypermucoviscous phenotype was seen in 24% of these isolates, the prevalence of
K1 and K2 were 40.6% and 31.9%, respectively. rmpA and magA were strongly
associated with viscous phenotype (Yeh et al., 2010; Hsu et al., 2011).
The rmpA/rmpA2 genes (regulator of the mucoid phenotype) mediate the
hyper-expression of the capsular material coding genes and can be both
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chromosomally and plasmid encoded. Once on a plasmid, its size is 180–220 kb which
may also code for other factors that may be involved in virulence. (Hsu et al., 2011)
Once again, a very close association was found between these regulators and the hvKP
character (Yeh et al., 2010; Hsu et al., 2011).
These capsule types may also be present in strains colonizing the intestinal
tract. Investigating stool specimens from 954 healthy Chinese adults who were
residents of Taiwan, Hong Kong or China or were living abroad in Japan, Thailand,
Malaysia, Singapore and Vietnam K. pneumoniae was isolated from 592 individuals
and of them, 4% of the strains carried K1, while 2% expressed K2 capsular types
(Brisse et al., 2009). Similar results were obtained in a separate study in South Korea
showing that of the 248 K. pneumoniae strains isolated from stool samples of healthy
carriers 4.9% carried the K1 capsule type (Cheng et al., 2012).
In China, (Yinjuan, 2017): nearly all (95.2%) K1, K2, K5, K20 and K57
isolates with hypermucoviscosity phenotype were positive for rmpA. Furthermore, this
study could also show a close association between mrkD and the K2 capsular type
isolates (Yinjuan, 2017). A similarly important finding of this study was that
aerobactin-coding genes iucA was present in 95.1% of the hyperviscous strains and
only in 41.1% of HMKP of the non-hyperviscous isolates.
Actually, the association with iron acquisition mechanisms were shown in K2
capsule type strains, too, as they produced more iron-acquisition factors than there
“classic”, cKP counterparts (Russo et al., 2011). Indeed, and increasing body of
evidences suggest that beyond surface properties, as capsular types, iron acquisition
plays a central role in increasing the pathogenic potential of K. pneumoniae to the
extreme converting the isolate to “hypervirulent”. A recent study found that the
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biosynthesis of siderophore aerobactin, coded by the iuc gene, and that of salmochelin
(iro) are closely linked to hypervirulent K. pneumoniae clones causing invasive
community-associated infections, such as liver abscess and pneumonia. It was also
found that when examining the genome of 2503 K. pneumoniae isolates not known to
be hypervirulent, iuc was detected in 8.7% and iro was presents in 7.2%, only (Russo
et al., 2015).
In another study, among K. pneumoniae causing severe community-acquired
(CA) infections, such as pyogenic liver abscess, pneumoniae and meningitis of
neonates, i.e. features of hvKP, the presence of acquired siderophores genes was also
common (Holt et al., 2015).
A number of other factors may also contribute to the colonization and invasion
across the intestinal barrier such as the LPS, Outer Membrane Protein (OMP), genes
associate with the intestinal colonization, but they seem to be less specific to the hvKP
character than rmpA/A2 and iuc (Struve et al., 2003; Ma et al., 2005; Hsieh et al., 2008;
Wu et al., 2011). The metabolism of allantoin is a process by which bacteria can obtain
carbon and nitrogen from their environment (Paczosa and Mecsas, 2016). In a search
of K. pneumoniae genes whose transcription was upregulated in HV K. pneumoniae
strains compared to classical strains, an operon containing genes involved in allantoin
metabolism was identified. The deletion of allS, an activator of this operon, resulted
in an HV K. pneumoniae strain with significantly reduced virulence in an intragastric
model of infection (Chou et al., 2004). A study by Yu et al., 2008, found that allS was
present in 100% of HV K. pneumoniae isolates from Taiwan but it was absent in K2
isolates and non-K1/K2 isolates from patient blood or liver samples (Yu et al., 2008).
The hvKP character is, at least to some extent, associated with certain clones.
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The most predominant sequence typing strongly associated with hvKP is sequence
type (ST) 23 and that is linked with K1 capsular serotype and liver abscess (Pitt et al.,
2007; Peck et al., 2008; Decre et al., 2011). Furthermore, ST86, ST375 and ST380
are mainly associated with K2 serotype (Jung, 2013). A study in South Korea showed
that, nearly all (94.7%) of the K1 capsule type strains (representing 4.9% of all K.
pneumoniae isolated from fecal samples of healthy individuals) belonged to ST23
(Cheng et al., 2012).
1.3.3 Bloodstream infections caused by Klebsiella pneumoniae
K. pneumoniae, just like E. coli, has been implicated in practically every kind
of extraintestinal infections including urinary tract infections, tissue infections and
pulmonary infections (Bennett et al., 1995; Lye et al., 1992; Siu et al., 2012). In South
America, Klebsiella pneumoniae represents the third most prevalent pathogen isolated
from the respiratory tract of patients with pneumonia and it represents 12% of all
pathogens isolated (Marra et al., 2006). While these focal or more or less localized
infections can have serious consequences on their own, they can also be the source of
bloodstream infections (BSI) (Fader and Davis, 1980).
The status of the host defense contributes in two ways to the development of
BSIs. On one hand, the initial focal infection is more likely to develop in patients with
predisposing conditions and weaknesses (e.g. catheterized patients, ventilated patients,
immunosuppressed patients). On the other hand, weak defenses decrease the chances
to control the infection locally, and hence, increases the chances that the infection
reaches the bloodstream.
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Seeing an increase number of patients with decreased immunocompetence,
either due to their comorbidities (e.g. malignancies) or to the medical interventions,
the number of BSIs caused by K. pneumoniae continue to increase worldwide
(Podschun et al., 2001). Actually, K. pneumoniae considered as the second most
common pathogen in the family Enterobacteriaceae which causes BSIs (Podschun et
al., 2001). Recently, international published observational study found that among the
1,156 ICU patients with BSI from all over the world 57.6% were caused by Gramnegative bacteria of which 38% was K. pneumoniae (Russotto et al., 2015).
1.3.3.1 Bloodstream infections in patients with malignancy
Bloodstream infections (BSI) are a major cause of critical complications in
patients with cancer and are directly connected with extended hospital stay, expensive
healthcare costs and high risk of morbidity and mortality. The overall rate of mortality
of BSI in cancer patients is reported to be 25–32%. Bacteria represent the most
common cause (Obeng-Nkrumah et al., 2015).
Recently, a shift from Gram-positive to Gram-negative organisms has been
acknowledged in the etiology of BSI with considerable variation according to
geographic location (Munoz-Price et al., 2013). It has been found that Gram-negative
bacteria were the most frequent contributory agents isolated in BSIs in malignant
patients. It has been noticed that K. pneumoniae, E. coli, and P. aeruginosa are the
main microorganisms involved in BSIs and are the same microorganisms which are
responsible for bacteremia as reported in Europe (Lon et al., 2019).
In a recent study in Mexico, it was found that 14% of patients with solid tumors
developed a BSI, the ranges were from 1.2 to 1.6 cases per 1,000 patients admitted
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with solid malignancies per year. In the United States, the incidence of sepsis in
patients with cancer in a similar setting is about 16.4 (including hematology patients)
(Lon et al., 2019).
The role of the compromised defense capacities due to malignancies have been
well-illustrated by a study from Taiwan. A total of 158 cases of K. pneumoniae
bacteremia were analyzed. 40.5% of them were considered nosocomial and the most
common underlying disease was neoplasia (53%), followed by hepatobiliary diseases
(22%) and diabetes mellitus (n = 8,12 %) (Chang et al., 2002).
The mortality rate of K. pneumoniae BSIs varies from 15 to 79% (Xu, et al.,
2018), which is lower if compared to Acinetobacter baumannii BSIs (30 to 84%) but
higher than Escherichia coli (5 to 22%) (Xu et al., 2018).
Beyond the actual virulence of the strains, the other major microbial factor that
impacts the outcome of infections is the resistance to antibiotics (Xu et al., 2018)
(Kakeya et al., 2016). In Italy, in a recent study on patients with haematological
malignancies, of the 22 patients colonized with carbapenem resistant K. pneumoniae
(CRKP) 14 (64%) patients developed bacteremia (Fo et al., 2017). It is noteworthy
due to the potentially grave consequences as BSI caused by CRKP have become a very
serious problem with associated mortality as high as 40–60% (Giacobbe et al., 2015).
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1.4 Antibiotic resistance of Klebsiella pneumoniae
Antibiotics resistance, and in particular multi-drug resistance (MDR) became
a severe, global burden on healthcare. The CDC identified those organisms which
represent the most urgent threats of antibiotic resistance Table 3 (CDC, 2018).
Table 3: The categories of urgent threats of antibiotic resistant bacteria (CDC, 2018)
Category
Urgent Threats

Serious Threats

Concerning
Threats

Pathogens
Clostridium difficile
Carbapenem-resistant Enterobacteriaceae (CRE)
Drug-resistant Neisseria gonorrhoeae
Multidrug-resistant Acinetobacter
Drug-resistant Campylobacter
Fluconazole-resistant Candida (a fungus)
ESBL producing Enterobacteriaceae (ESBLs)
Vancomycin-resistant Enterococcus (VRE)
Multidrug-resistant Pseudomonas aeruginosa
Drug-resistant non-typhoidal Salmonella
Drug-resistant Salmonella Typhi
Drug-resistant Shigella
Methicillin-resistant Staphylococcus aureus (MRSA)
Drug-resistant Streptococcus pneumoniae
Drug-resistant tuberculosis
Vancomycin-resistant Staphylococcus aureus (VRSA)
Erythromycin-resistant Group A Streptococcus
Clindamycin-resistant Group B Streptococcus

It should be noted that Enterobacteriaceae, that includes K. pneumoniae, once
developing resistance to the most advanced beta-lactams, i.e. carbapenems, are on the
top of the list.
Antibiotics are natural products of microorganisms with the role of inhibiting
the growth of other microorganisms competing for the same niche. This antimicrobial
activity is being used in medicine, although in most cases the natural products are
further modified, or in some cases, completely synthetized (e.g. chloramphenicol).
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Antibacterial drugs can be either bactericidal or bacteriostatic depending on the
species and the drug, and in some cases its concentration (Aminov, 2010). Antibiotics
are grouped by their mode of action as shown in Table 4 (Murray, 2013; CDC, 2018).
Table 4: Main mode of action of antibiotics (CDC, 2018)
Mode of action
Inhibition of cell wall synthesis
Inhibition of protein synthesis
Interference with nucleic acid
synthesis
Cell membrane disruption
Antimetabolites

Examples
ß-lactams, glycopeptides, fosfomycin
aminoglycosides, macrolides,
tetracyclines, chloramphenicol
quinolones, fluoroquinolones, rifampin
polymyxins
sulfonamides, trimethoprim

The most common mechanisms by which bacteria could express resistance to
antibiotics are the enzymatic degradation of the drug, the target alteration of its cellular
target while preserving its original function, the decrease of its intercellular
concentration either by decreasing its uptake or by increasing its expulsion by
upregulating efflux pumps, protecting the target from the access of antibiotics and
finally overproducing the target. Depending of the species and the drug, any of these
mechanisms could be part of the natural or the acquired resistance mechanism of
bacteria (Munita and Arias, 2016).
Acquired resistance can be the result of mutations or a cell might pick-up
resistance gene(s) by taking up mobile genetic elements, such as plasmids via
horizontal gene transfer (HGT) (Read and Woods, 2014; Zaman et al., 2017).
A broad range of antibiotics can theoretically be used to treat different K.
pneumoniae infections, i.e. the species does not have natural resistance against them.
However, experience showed that K. pneumoniae is particularly capable of developing
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acquired resistance. Therefore, in practice, the list of drugs available to treat K.
pneumoniae systemic and bloodstream infections (BSI) are often dangerously limited
and includes ß-lactams, aminoglycosides, tigecycline, fluoroquinolones and
polymyxins. Below, a brief discussion will be limited to these groups of drugs, only,
together with the most common resistance mechanisms against them.
1.4.1 β-lactam antibiotics
One of the most common mechanism of antibiotic action is the inhibition of
cell wall synthesis and β-lactam antibiotics (e.g. penicillins, cephalosporins,
carbapenems and monobactams) are the most commonly used cell wall active
antibiotics (Nordmann et al., 2012). β-lactam antibiotics share a common β-lactam
ring which is a core structure essential to their bacterial activity. The structures of the
four groups of ß-lactam antibiotics are shown in Figure 5.

Figure 5: Chemical structures of the main β-lactams and β-lactamase inhibitors
(Nordmann et al., 2012)
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1.4.1.1 Penicillins
Penicillins are classified according to their spectra of antimicrobial activity.
The first group includes the natural penicillin G (benzylpenicillin) and its
phenoxymethyl derivative, penicillin V, both are effective against β-lactamase nonproducing Gram-positive aerobic organisms including Streptococcus, against
anaerobes, like Clostridium spp. and against some Gram-negative bacteria, like
Neisseria

meningitidis.

Nowadays,

penicillinase-resistant penicillins include

methicillin, nafcillin, oxacillin, cloxacillin and dicloxacillin and they are mainly
affective against Staphylococcus spp. that produce penicillinase. Ampicillin and
amoxicillin belong to the third group called aminopenicillins and their antimicrobial
activity is extended to include Gram-negative organisms, such as Haemophilus
influenzae, E. coli and Proteus mirabilis. In the fourth group called ureidopenicillins,
i.e. cabenicillin, ticarcillin, mezlocillin and piperacillin, are drugs having increased
activity towards Gram-negative and anærobic organisms including Pseudomonas spp.
(Jacoby and George, 2010; Nordmann et al., 2010).
Penicillins, particularly members of the first three groups, and particularly if
applied without any beta-lactamase inhibitor (see later) have very little role in treating
K. pneumoniae infections due to their resident β-lactamase (SHV) gene (Livermore et
al., 2007; Sutaria et al., 2018).
1.4.1.2 Cephalosporins
The cephalosporins are derived from 7-amiocephalosporanic acid as the βlactam ring is fused with a dihydrothiazine ring (Murray, 2013). They are divided into
five generations. Through generations 1-3 the spectrum of cephalosporins has
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gradually drifted towards Gram-negative cells with somewhat decreasing activity
against Gram-positive organisms. The 3rd and 4th generation cephalosporins are
extensively used for the treatment of K. pneumoniae infections (Cole et al., 2015; Lee
et al., 2015). The 5th generation drugs are active against MRSA due to their increased
affinity to PBPs.
The classification of cephalosporins generations in Table 5 is based on the
general features of antimicrobial activity (Dancer, 2001).
Table 5: The generations of cephalosporins
Generations
First Generation:
Cefazolin
Cephalexin monhydrate
Cefadroxil
Cephradine
Second Generation:
Cefuroxime
Cefuroxime axetil
Cefprozil
Cefmetazole
Loracarbef

Third Generation:
Cefotaxime
Ceftriaxone
Cefdinir
Cefditoren pivoxil
Ceftibuten
Cefpodoxime proxetil
Ceftizoxime
Cefoperazone
Ceftazidime
Fourth Generation:
Cefepime
Fifth Generation:
Ceftobiprole
Ceftaroline

Spectrum

Streptococci, Staphylococcus aureus

Escherichia coli, Klebsiella, Proteus,
Haemophilius influenzae, Moraxella
catarrhalis. Not as active against grampositve organisms as first-generation
agents.
Inferrior activity against S. aureus
compared to cefuroxime but with added
activity against Bacteroides fragilis and
other Bacteroides spp.
Enterobacteriaceae, Pseudomonas
aeruginosa, Serratia, Neisseria
gonorrhoeae, activity for S. aureus,
Streptococcus pneumoniae, and
Streptococcus pyogenes comparable to
first-generation agents. Activity against
Bacteroides spp. inferior to that of
cefoxitin and cefotetan
Active against Pseudomonas
Comparable to third generation but
resistant to Beta-lactamase
Active against MRSA
Not resistant to ESBL
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1.4.1.3 Monobactams
Aztreonam is the main representative of monobactams. They have a narrow
spectrum activity against aerobic Gram-negative microorganisms without any activity
against Gram-positive bacteria. While having not been used extensively, lately there
are likely to experience an increased importance of aztreonam, as this is the only group
of beta-lactams that are resistant to metallo-beta-lactamases (MBL) (Vardanyan and
Hruby, 2016).
1.4.1.4 Carbapenems
Members of this group (e.g. imipenem, meropenem, ertapenem and
doripenem) have the broadest spectrum of all ß-lactams against both Gram-positive
and

Gram-negative

organisms.

Importantly,

non-fermenting

bacteria

(e.g.

Acinetobacter and Pseudomonas spp.) have natural resistance against ertapenem.
Many MDR Gram-negative strains are still sensitive to carbapenems and hence, today,
they are the ultimate drugs used to treat various life threatining Gram-negative
infections. (Bush and Karen, 2007; Papp-Wallace et al., 2011). That is why the fast
emergence and spread of carbapenem resistance in Enterobacteriaceae (CRE) and that
in K. pneumoniae (CRKP) is such a serious threat (CDC, 2018).
1.4.2 Resistance to β-lactams antibiotics
There are three main mechanisms by which bacteria can resist β-lactams: target
modification, decreased intracellular concentration and by the production of betalactamase enzymes.

27
1.4.2.1 Target alteration
This is a common and highly effective mechanism in several Gram-positive
bacteria (e.g. in methicillin resistant Staphylococcus aureus, MRSA or in
Streptoccoccus pneumoniae), and is also present in some Gram-negative ones (e.g. the
ß-lactamase negative, ampicillin resistant (BLNAR) strains of Haemophilus influenzae
(Dever and Dermody, 1991; Lambert, 2005; Tristram et al., 2007). However, in
converting Enterobacteriaceae to ß-lactam resistant it has limited, if any role, hence it
will not be further discussed here.
1.4.2.2 Decreasing intracellular concentration
The intracellular concentration of a drug can be limited by two ways: by
expelling molecules already taken up or by limiting their uptake. The first mechanism
is usually achieved by the up regulation of the expression of efflux pumps (Poole,
2005; Webber and Piddock, 2003). These efflux pumps vary in their spectrum of
compounds as they can expel from the cell, but often they are multi-drug efflux pumps
(Aeschlimann, 2003; Rouveix, 2007; Sun et al., 2014). Although this spectrum may
include various ß-lactam drugs in Enterobacteriaceae, in their cephalosporin and
carbapenem resistance efflux pumps play a comparatively minor role, seldom leading
to clinically significant level of resistance to these agents (Pages et al., 2009).
The other mechanism is the modification of porins that form channels in the
outer membrane or limiting their numbers with a consequent limited uptake of the
drugs (Yang et al., 2010; Nikaido, 1989; Doumith et al., 2009). This mechanism has
considerable effectiveness in Enterobacteriaceae in lowering the susceptibility to
cephalosporins and carbapenems (Pages et al., 2008; Wozniak et al., 2012). Even if
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the restriction of uptake may not result in clinically significant reduction of
susceptibility, once combined with the production of hydrolytic enzymes even with
moderate activity against a particular extended spectrum beta-lactam, the combined
effect of these two mechanisms can cause clinically significant cephalosporin or even
carbapenem resistance.
1.4.2.3 Enzymatic degradation of β-lactams
Enzymatic inactivation of β-lactam agents is the most common and most
effective resistance mechanism among Enterobacteriaceae against this group of
antibiotics (Murray, 2013).
There are two main classification schemes for ß-lactamases that are currently
in use. The Ambler molecular system, based on conserved and distinguishing amino
acid motifs, classifies β-lactamases into four molecular classes, i.e. A, B, C, and D,
(Table 6). On the other hand, grouping by the Bush-Jacoby-Medeiros system is based
on the functional similarities (including substrate spectrum, EDTA and susceptibility
to inhibitors, such as clavulanic acid, sulbactam and tazobactam) of the various
enzymes forming four main, and multiple subgroups (Table 6) (Ambler, 1980; Bush
and Jacoby, 2010; Hall and Barlow, 2005).

Table 6: Classification of β-lactamases (Bush and Jacoby, 2010; Bush et al., 1995)
Molecular
class

BushJacobyMedeiros

Active
site

2a
2b
2be
2br
2c
2e
2f

Serine

B

3

Zn2+

C

1
1e

Serine

A

Enzyme type

Substrates

Examples

Inhibitors

Comment

Penicillinases
Broad Spectrum

Aminopenicillins

TEM1
SHV1

Clavulanic acid

Plasmid
Chromosome

Extended Spectrum ßlactamases (ESBL)

Broad spectrum and
aztroneam

TEM-derived, CTXderived

Clavulanic acid

Plasmid

Carbapenemases

Extended spectrum plus
cephamycins

KPC-2
KPC-3

Clavulanic acid

Chromosome

Metallo-β-lactamases

Extended spectrum plus
cephamycins
Extended spectrum plus
cephamycins
Cloxacillin, methicillin

IMP, VIM, GIM,
NDM
AmpC-type

EDTA

Plasmid
Chromosome
Plasmid
Chromosome
Plasmid
Chromosome

Extended spectrum

Broad spectrum and
monobactams

OXA-derived in
P. aeruginosa

Clavulanic acid +/-

Plasmid
Chromosome

Carbapenemases

Extended spectrum plus
cephamycins

OXA-derived in
Acinetobacter

Clavulanic acid +/-

Plasmid
Chromosome

Cephalosporinases
Oxacillinases
Broad spectrum

D

2d

Serine

OXA-family in
P. aeruginosa

Cloxacillin
Monobactam
Clavulanic acid +/-
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Class A contains beta-lactamases with a broadly varying substrate specificity
from narrow spectrum penicillinases through extended-spectrum beta-lactamases
(EBLS) hydrolyzing 3rd and 4th generation cephalosporins to carbapenemases. Several,
but not all of them can characteristically be inhibited by β-lactamase inhibitors (see
later). Their genes are often located on plasmids; therefor they have the ability to
spread among members of the same species or even among different genera.
The best-known representatives of this group are TEM and SHV type enzymes.
The original molecules had relative narrow substrate spectrum. However, subsequent
mutations have resulted into the considerable extension of the spectrum also including
3rd and 4th generation cephalosporins (and in some case a low activity also against
carbapenems) (Fong and Drlica, 2003; Harvey et al., 2007; Rupp and Fey, 2003).
Currently, the CTX-M type of ESBLs, with characteristically high activity against
cefotaxime, represent a rapidly growing family of molecular class A ESBLs. In recent
years, the CTX-M type ESBLs became the most frequent ESBL type worldwide
(Bonnet, 2004; Cantón et al., 2008; Eisner et al., 2006; Zowawi et al., 2013).
Further members of this group are the enzymes with even broader activity
spectrum, i.e. carbapenemases. An important example is the K. pneumoniae
carbapenemases (KPC), first detected in USA in 1996, that is currently the most
common carbapenemases at several parts of the World (Arnold et al., 2011; Nordmann
et al., 2009; Sonnevend et al., 2015a; Won et al., 2011; Zowawi et al., 2014).
Molecular class B enzymes are the so-called metallo ß-lactamases (MBL) that
require a divalent cation for their activity and hence, can be inactivated by chelators,
such as EDTA or dipicolinic acid (DPA). There are several broad-spectrum enzymes
among them with activity against all ß-lactams (including carbapenems) with the
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notable exception of monobactams. Similarly, to group A enzymes, their genes can
often be found on mobile genetic elements. They are commonly present in nonfermenting bacteria, such as Pseudomonas and Acinetobacter¸ but also spreading fast
among Enterobacteriaceae. Examples of these enzymes are the VIM, IMP and the
recently emerging New Delhi Metallo ß-lactamases (NDM) (Cornaglia et al., 2011;
Ghazawi et al., 2012; Sonnevend et al., 2012; Walsh and Toleman, 2012).
The most important types of class C enzymes are the AmpC-type enzymes.
Some, if hyper-expressed, has broad spectrum activity which includes hydrolysis of
3rd and 4th generation cephalosporins, and in some cases have even a moderate, weak
activity against carbapenems. In some species the necessary high expression of the
enzyme to achieve clinical resistance is inducible by ß-lactam drugs, while in others
they are constitutively expressed (Hanson, 2003; Jacoby, 2009; Thomson, 2010).
Molecular class D enzymes are primarily oxacillinases (OXA) that vary
considerably in their spectrum. An important group even has carbapenemase activity,
although some of these enzymes exhibit simultaneously no or moderate activity
against cephalosporins (Evans and Amyes, 2014; Walther-Rasmussen and Høiby,
2006). They predominantly occur in various non-fermenting Gram-negative rods, but
currently a subset of them, the OXA-48-like enzymes, are fast spreading in
Enterobacteriaceae, as well (Ahn et al., 2015; Cantón et al., 2012).
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1.4.3 Beta-lactamase inhibitors
Beta-lactamase inhibitors (Figure 6) are the most powerful and clinically used
antibiotic adjuvants to counteract resistance to beta-lactam antibiotics. The main role
of these inhibitors is to protect the antibiotics from a very efficient bacterial
inactivation mechanism involving beta-lactamases (González-Bello, 2017).

Figure 6: Chemical structures of β-lactamase inhibitors (Docquier and Mangani,
2018)

The identification of inhibitors to common beta-lactamases started in the mid1970s, which was due to the appearance of the TEM-1 penicillinase in Neisseria
gonorrhoeae (Ashford et al., 1976) and Haemophilus influenzae (Gunn et al., 1974;
Khan et al., 1974). The first inhibitor discovered was clavulanic acid with a novel
clavam structure with an inhibitor activity against staphylococcal penicillinases and
most of the known plasmid-encoded penicillinases found in enteric bacteria (Reading
and Cole 1977; Cole, 1982), including the widespread TEM and SHV enzymes
(Simpson et al., 1980). Clavulanic acid is a so called “suicide inhibitor” as it is being
inactivated while interfering with the enzyme to be inhibited (Charnas et al., 1978;
Charnas and Knowles, 1981).
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Several, but not all, class A beta-lactamases, including ESBLs, can be inhibited
by clavulanic acid (Steward et al., 2001) and that applies to some extent even to some
of the class A carbapenemases (Nordmann and Poirel 2002; Yigit et al., 2003). Most
extensively it is used in combination with amoxicillin considerably extending the
spectrum of the drug particularly towards Gram-negative bacteria (Bush and Bradford,
2016).
After the discovery of clavulanic acid, chemists tried to synthesize a number
of penicillanic acid sulfones with beta-lactamase inhibitory activity (English et al.,
1978; Fisher et al., 1981; Aronoff et al., 1984). Of these, sulbactam (English et al.,
1978) and tazobactam (Aronoff et al., 1984) were effectively commercialized. These
two inhibitors had a similar range of activity as clavulanic acid. Sulbactam has
somewhat less inhibitory activity against class A beta-lactamases compared to
clavulanic acid or tazobactam but has an improved inhibition against class C
cephalosporinase enzimes (Bush et al., 1993). The sulfone inhibitors do not work as
inducers of chromosomally mediated AmpC Beta-lactamase (Weber and Sanders
1990). Sulbactam has been combined with ampicillin (Neu, 1990) and in Japan it has
been combined with cefoperazone to offer extra synergistic activity against nonfermentative and anaerobic bacteria (Eliopoulos et al., 1989). On the other hand,
tazobactam has been combined with piperacillin, cefoperazone and ceftolozane for
nosocomial infections, including those caused by P. aeruginosa (Lister, 2000).
Despite the structural similarities to “real” beta-lactam drugs, the inhibitors
usually have limited antibacterial activity on their own with some exceptions.
Clavulanic acid alone has an MIC as low as 1 mg/L against N. gonorrhoeae (Wise et
al., 1978); while sulbactam has intermediate activity against wild-type Acinetobacter
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spp. and Burkholderia cepacea, respectively (Jacoby and Sutton 1989; Fass et al.,
1990; Dong et al. 2014). Importantly, none of these inhibitors inhibit the hydrolytic
activity of MBLs (Bush, 2015), and that their activity against serine carbapenemases,
if present at all, is not sufficient to convert enzyme producing isolates into clinical
susceptibility (Yigit et al., 2003; Woodford et al., 2004; Moland et al., 2007).
After a gap of almost two decades, a new class of non-beta-lactam betalactamase inhibitors emerged based on a novel structure, i.e., diazabicyclooctane
(DBO) (Coleman, 2011). The first inhibitor of this class is Avibactam which has a
broader spectrum of activity than the previous inhibitors.
The success of avibactam can be attributed first to the unique structural
similarity to beta-lactams at the level of the electrophilic carbonyl group. This mimicry
is significant for rapid formation of a stable adduct by beta-lactamases. The stable acyl
enzyme formed by the carbamoyl link between the inhibitor and the enzyme activesite serine residue considered the second significant attribute of this compound (Drawz
et al., 2014).
Avibactam can effectively inhibit not only class A penicillinases, ESBLs, and
serine carbapenemases, but also class C cephalosporinases and some class D
oxacillinases (Ehmann et al., 2012, 2013). It does not induce AmpC beta-lactamases
at clinically applicable concentrations (Coleman, 2011). Avibactam, in combination
with ceftazidime, has been approved in late 2014 by the FDA to treat complicated
intra-abdominal and complicated urinary tract infections (González-Bello, 2017).
Some other DBOs which are under development include RG6080 and
relebactam (MK7655), in combination with imipenem-cilastatin. The inhibitory
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spectrum of relebactam is similar to that of avibactam; however, except that it does
not inhibit class D beta-lactamases, such as OXA-48 (Livermore et al., 2013). The
other inhibitor RG6080 (earlier known as OP0565) is a DBO that has similar inhibitory
spectrum to the other DBOs, but it has the extra benefit of showing some natural
antibacterial activity against enteric bacteria (Livermore et al., 2015). The RPX7009
(boronic acid) inhibitor is another new class of synthetic non-b-lactam b-lactamase
inhibitors (Hecker et al., 2015). It has inhibitory activity against many groups of serine
beta-lactamases (Hecker et al., 2015).
None of these promising inhibitors has activity against class B enzymes.
However, clinical trials using aztreonam in combination with ceftazidime are
promising. MBLs do not hydrolyze aztreonam and the avibactam added may inhibit
practically all, non MBL type beta-lactamases. (Drawz et al., 2014).
1.4.4 Aminoglycosides
The discovery of aminoglycosides through systematic screening of soil
Actinobacteria started in the 1940s. Streptomycin was the first aminoglycoside to be
discovered from Streptomyces griseus and since then, it has been successfully used for
the treatment of tuberculosis and infections with Gram-negative bacteria (Doi et al.,
2016). The name “aminoglycoside” derives from the classic structure of these
antibiotics having an amino-containing or non-amino-containing sugar residue
connected to six-membered rings with amino group substituents. Subsequently,
numerous aminoglycosides (Figure 7) have been identified or semi-synthesized and
used in clinical practice. Based on their chemical structures, the aminoglycosides are
grouped into 4,6-disubstituted 2-deoxystreptamine (DOS), 4,5-disubstituted DOS, and
4-monosubstituted DOS.
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Figure 7: Structures of representative aminoglycosides (Krause et al., 2016)

The first group includes gentamicin, tobramycin, and amikacin, which have
been extensively used as intravenous or nebulized formulations in combination with a
beta-lactam for the treatment of infections caused by Gram-negative bacteria, and
atypical mycobacteria (also in combination with other active agents). The second
group is represented by neomycin, which are limited in their use for being toxic and
are given either orally or topically, but not intravenously. The monosubstituted DOS
group is represented by apramycin, which is mainly used in veterinary medicine (Doi
et al., 2016). Lately, a new semisynthetic version, plazomicin, was introduced to
clinical practice, that is able to resist the most aminoglycoside destroying mechanisms
(Petrosillo et al., 2019).
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Aminoglycosides lead to inhibition of polypeptide synthesis and to subsequent
cell death by binding to the aminoacyl-tRNA recognition site (A-site) of the 16S rRNA
which constitutes the 30S ribosomal subunit. They are the only protein synthesis
inhibitor antibiotics with a bactericidal effect against most susceptible pathogens (Doi
et al., 2016; Serio et al., 2018).
1.4.4.1 Resistance to aminoglycosides
There are several mechanisms by which bacteria can confer resistance to
aminoglycosides of which: (1) enzymatic modification and inactivation of the
aminoglycosides,

mediated

by

aminoglycoside

acetyltransferases,

nucleotidyltransferases, or phosphotransferases (Ramirez and Tolmasky, 2010; Shaw
et al., 1993); (2) increased efflux; (3) decreased permeability; and (4) modifications of
the 30S ribosomal subunit; (5) target site modification which occurs through the action
of 16S rRNA methyltransferases (RMTs). Mechanisms 1-4. have varying effects on
different members of the class and frequently multiple mechanisms are involved in
any given resistant isolate. Nevertheless, by choosing the right representative, often
there is a chance to find a drug that is still clinically active. On the other hand,
modification of the 16S ribosomal site usually affects most clinically relevant
aminoglycosides (Krause et al., 2016; Takahashi and Igarashi., 2018) seriously
restricting the use of these antibiotics. Hence, in the following paragraph, the focus
will be on the 16S RMTs.
RMTs consist of two main classes depending on the specific nucleotide
residues that they modify. The first class includes enzymes that make the bacteria
resistant to 4,6-di-substituted aminoglycosides via methylation of the N7 position of
nucleotide G1405 (Thompson et al., 1985; Beauclerk and Cundliffe 1987) while the
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other class affects both 4,6- and 4,5-di-substituted aminoglycosides through
methylation of the N1 position of nucleotide A1408 (Skeggs et al., 1985; Beauclerk
and Cundliffe 1987; Mingeot-Leclercq et al., 1999).
The first RMT described was armA in Klebsiella pneumoniae and rmtA in
Pseudomonas aeruginosa (Galimand et al., 2003; Yokoyama et al., 2003). The armA
gene was first reported in an isolate of K. pneumoniae from the urine of a patient in
Paris in 2000 (Galimand et al., 2003; Gniadkowski et al., 1998). armA was later
confirmed to function as N7- G1405 16S-RMTase (Liou et al., 2006). rmtA was
identified in a sputum isolate of P. aeruginosa in Japan in 1997 (Yokoyama et al.,
2003). Since then several others were described (Table 7) (Doi et al., 2016).
Of the enzymes methylating at N1 A1408 position only a single representative
has so far been described: npmA, was reported from an Escherichia coli clinical strain
in Japan in 2007 (Wachino et al., 2007). It confers an even wider spectrum of
aminoglycoside resistance than the N7 methylating ones including neomycin and
apramycin (Dunkle et al., 2014). Importantly, several of these genes are located on
plasmids, often also carrying other resistance genes (Doi et al., 2016).

39
Table 7: Acquired 16S-RMTases (Doi et al., 2016)
16SRMTase

Common
Species

Common
Co-resistance
CTX-M ESBL,
NDM
carbapenemase,
OXA-23
carbapenemase

Prevalence

Distribution

Very high in
A baumannii
High among
NDM
producers

Worldwide

Low

Japan, Korea

armA

K. pneumoniae
A. baumannii

rmtA

P. aeruginosa

rmtB

E. coli
K. pneumoniae

CTX-M ESBL,
NDM
carbapenemase

rmtC

K. pneumoniae
P. mirabilis

NDM
carbapenemase

rmtD

P. aeruginosa
K. pneumoniae

CTX-M ESBL,
KPC
carbapenemase

Low

South
America

rmtE

E. coli

CMY-2 AmpC

Very low

United States

rmtF

K. pneumoniae

NDM
carbapenemase

High among
NDM
producers

India, United
Kingdom

rmtG

K. pneumoniae

CTX-M ESBL,
KPC
carbapenemase

Low

South
America

rmtH

K. pneumoniae

CTX-M ESBL

Very low

Iraq

npmA

E. coli,
K. pneumoniae
Enterobacter
spp.

Very low

Japan, Saudi
Arabia

—

—

High in China
High among
NDM
producers
High among
NDM
producers

Worldwide

India, United
Kingdom

1.4.5 Tigecycline
Tigecycline is a glycylcycline antimicrobial agent that is structurally related to
minocycline (Sun et al., 2013). Tigecycline can enter the bacterial cell by active
transport or passive diffusion and, in the same way as tetracyclines, the antibiotic binds
reversibly to the 30S ribosomal subunit, hindering the entry of tRNA into the A site of
the ribosome therefore preventing the elongation of peptide chains and thus limiting
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the bacterial growth (Noskin, 2005; Hirata et al., 2004; Hope et al., 2010; Khardori,
2006). The addition of an N,N,-dimethylglycylamido group at the 9 position of the
minocycline molecule increases the affinity of tigecycline for the ribosomal target up
to 5 times when compared with minocycline or tetracycline (Nathwani, 2005).
Tigecycline has a broad range of activity against many Gram-positive (such as
MRSA and MRSE, penicillin-resistant Streptococcus pneumoniae, and VRE species),
gram-negative (Citrobacter freundii, Escherichia coli, Enterobacter cloacae,
Klebsiella species, Salmonella species, Serratia marcescens, and Shigella species) and
anaerobic organisms (Zhanel et al., 2004; Nathwani, 2005; Fritsche and Jone, 2004).
Activity of tigecycline and minocycline can also cover Acinetobacter species (PachonIbanez et al., 2004). None of the tetracyclines have coverage against Pseudomonas
aeruginosa. Tigecycline also does not have activity against certain Proteus strains,
including Proteus mirabilis. A major disadvantage of tigecycline is its short half live
in serum, so its main use is in soft tissue infections intrabdominal and lately,
pneumonias (Stein and Babinchak, 2013; Wang et al., 2017).
1.4.5.1 Resistance to tigecycline
It has been reported that tigecycline is not affected by most of the common
mechanisms of antibiotic resistance used by bacteria to avoid antibiotic therapy, due
to the steric hindrance gained by the large D-ring substituent (Pankey, 2005).
However, emergence of tigecycline resistance in K. pneumoniae isolates has been
reported (Elgendy et al., 2018). Overexpression of rarA, a transcriptional activator of
the oqxAB efflux pump, can induce a low level of resistance to tigecycline in K.
pneumoniae (Elgendy et al., 2018).
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Based on large-scale surveillance studies, tigecycline appears to hold low
resistance rates of <10% among Enterobacteriaceae worldwide (Pournaras et al.,
2016). An overall non-susceptibility rate of <10% including ESBL-producing
Enterobacteriaceae and CR K. pneumoniae, and <20% for MDR Enterobacteriaceae
and CR Enterobacter spp. and S. marcescens was reported (Pournaras et al., 2016).
On a worldwide basis, it has been found that E. coli exhibits lower non-susceptibility
rates if compared to K. pneumoniae, E. aerogenes, E. cloacae and S. marcescens
(Fern´andez et al., 2012). Using next-generation sequencing, Zheng et al identified
several genes which probably encode efflux pumps or translational regulators in
tigecycline-resistant K. pneumoniae, based on their sequence similarity to known RND
efflux pump genes which can be related to tigecycline resistance (Zheng et al., 2014).
It is clear that Tigecycline resistance mechanisms are complex in Enterobacteriaceae
(Table 8) (Zheng et al., 2014; Wang et al., 2015; Pournaras et al., 2016).
Table 8: Mechanisms implicated in tigecycline resistance among Enterobacteriaceae
(Pournaras et al., 2016)
Pathogen

Klebsiella pneumonia

Enterobacter cloacae and Enterobacter
aerogenes
Escherichia coli
Proteus mirabilis
Morganella morganii
Serratia marcescens

Suggested mechanism of tigecycline resistance
Overexpression of ramA and acrAB
Deletions, insertions and point mutations in ramR
Overexpression of rarA and oqxB
IS5 element integration in a putative efflux pump, KpgABC
Overexpression of marA and acrAB
Structural alteration of the ribosomal protein S10
Other RND efflux pump genes
RamA- mediated mechanisms affecting AcrAB regulation
AcrAB and AcrEF RND efflux pumps
Single nucleotide insertion in marR/ overexpression of MarA
AcrAB efflux pump
AcrAB efflux pump
Upregulation of SdeXY–HasF efflux pump

IS, insertion sequence; RND, resistance–nodulation–cell division.

1.4.6 Fluoroquinolones
The quinolones are a group of synthetic antimicrobial agents with major
clinical relevance. They have been one of the most frequently prescribed antimicrobial
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agents in the world. Initially, they were mostly used to treat Gram-negative infections,
later they were modified in order to improve their pharmacokinetic properties and
extend their antibacterial spectrum, to become effective against a wide variety of
Gram-negative and Gram-positive pathogens (Correia et al., 2017).
Nalidixic acid, as the first compound of the quinolones, was introduced into
clinical use in 1962, for the treatment of uncomplicated urinary tract infections (UTIs)
(Fàbrega et al., 2009; Bisacchi, 2015). The second generation of compounds, the
fluoroquinolones, showed significantly improved activity and enhanced Grampositive penetration and better pharmacokinetic and pharmacodynamic properties
(Aldred et al., 2014). The first representative of this generation was norfloxacin but
ciprofloxacin, the most widely used representative, showed good activity also outside
the urinary tract (Bisacchi, 2015). Even after almost three decades in clinical use, the
World Health Organization (WHO) listed ciprofloxacin as an essential, critically
important antibiotic (Collignon et al., 2016). The huge success of ciprofloxacin led to
the development of a newer generation of quinolones (levofloxacin, moxifloxacin,
gatifloxacin, etc.) with broader and different spectrum of activity and pharmacokinetic
properties (Aldred et al., 2014). Fluoroquinolones have been used comprehensively
for multiple clinical indications worldwide due to their power, wide activity spectrum,
oral bioavailability and generally good safety profile (Hooper and Jacoby, 2016).
The quinolones are known to target and inhibit the activity of two necessary
bacterial type II topoisomerases: DNA gyrase and topoisomerase IV, respectively
which play a vital role in the modulation of the chromosomal supercoiling required for
DNA synthesis, transcription and cell division (Aldred et al., 2014; Kohanski et al.,
2010).
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The number of quinolone-resistant strains has been growing steadily, being
observed in all species exposed to this antimicrobial class (Aldred et al., 2014; WHO,
2014; Hooper and Jacoby, 2016).
1.4.6.1 Resistance to fluoroquinolones
Quinolone resistance can be due to several mechanisms (Figure 8).
Chromosomally encoded mechanism are mutations modifying the target enzymes and
their drug-binding affinity and those leading to reduced drug accumulation by either
decreased uptake or increased efflux. Plasmid-coded resistance can be due to the
production of proteins protecting the drug’s and to the expression of drug modifying
enzymes (Aldred et al., 2014; Hooper and Jacoby, 2016; Kim and Hooper, 2014).
These mechanisms often co-exist and act concomitantly leading to high levels of
quinolone resistance (Hopkins et al., 2005; Hooper and Jacoby, 2016).

Figure 8: Mechanisms of quinolone resistance (Correia et al., 2017)
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Plasmid-mediated quinolone resistance (PMQR) is of particular importance
due to the easy spread via conjugation. The first target-protecting mechanism was
described in the late 1990s and have been broadly reviewed in the last decade (Jacoby
et al., 2014; Rodríguez-Martínez et al., 2016; Ruiz et al., 2012). The first PMQR gene,
qnrA, was reported in 1998 in a conjugative plasmid of a ciprofloxacin-resistant K.
pneumoniae clinical isolate (Martínez-Martínez et al., 1998) and, nowadays, about 100
Qnr variants have been identified, which has been classified into six distinct families:
QnrA, QnrB, QnrS, QnrC, QnrD and QnrVC. It has been found that the Qnr proteins
belong to the pentapeptide-repeat protein family and provide quinolone resistance by
physically protecting DNA gyrase and topoisomerase IV from quinolone inhibition
(Correia et al., 2017).
The second mechanism for PMQR was discovered in 2006 as a bifunctional
variant of an aminoglycoside-modifying acetyltransferase, AAC(6')- Ib-cr, that has
two specific amino acid substitutions (Trp102Arg and Asp179Tyr). This variation
made it able to acetylate the unsubstituted nitrogen of the C7 piperazine ring, which is
present in quinolones such as ciprofloxacin, thus conferring quinolone resistance by
decreasing the drug's activity. Soon after, a third mechanism for PMQR was found
with the discovery of the plasmid- encoded efflux pumps QepA and OqxAB (Correia
et al., 2017).
In the presence of therapeutic levels of quinolones, PMQR provides a good
background for selection of additional resistance mechanisms and hence for the
emergence of high levels of quinolone resistance. It has been reported that PMQR
genes found in transposons and/or integrons that are often co-located with other
resistance determinants (frequently with extended spectrum B-lactamase, AmpC-type

45
B-lactamase and carbapenemase genes) in MDR plasmids of significantly varying
sizes and incompatibility groups. The circulation of multiple plasmids with such
heterogeneity has been accountable for the wide geographic distribution of PMQR in
a great variety of hosts (Correia et al., 2017).
1.4.7 Polymyxins
In an era of enormous and growing threat of increased bacterial resistance to
almost all available antibiotics, drugs, such as the polymyxins, previously confined to
topical use, only due to their toxicity are re-entering the therapeutic armory against
Gram-negative bacteria (Yu et al., 2015; Poirel et al., 2017). Consequently,
polymyxins are often considered as the last option of antibiotic therapy for MDR
bacteria (Rice, 2006; Li and Nation, 2006).
The polymyxins consist of polymyxins A till E, of which only polymyxin B
and polymyxin E (colistin) are now used clinically. In general, both have a narrow
antibacterial spectrum restricted to Gram-negative bacteria (Li et al., 2007). Most
members of the Enterobacteriaceae family, including Escherichia coli, Enterobacter
spp., Klebsiella spp., Citrobacter spp., Salmonella spp., and Shigella spp.) and the
common non-fermenters (Acinetobacter baumannii, Pseudomonas aeruginosa, and
Stenotrophomonas maltophilia) are naturally susceptible (Falagas and Kasiakou,
2005). Some species are naturally resistant to polymyxins, including Proteus spp.,
Morganella morganii, Providencia spp., Serratia marcescens. Polymyxins are not
active against Gram-negative cocci (Neisseria spp.), Gram-positive bacteria, and
anaerobic bacteria (Falagas and Kasiakou, 2005).
Colistin (also known as polymyxin E) was originally isolated in 1947 from the
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soil bacterium Paenibacillus polymyxa subsp. colistinus (Benedict and Langlykke,
1947; Biswas et al., 2012). In the 1980s, the parenteral use of polymyxin was almost
completely abandoned due to the emergence of less-toxic aminoglycosides and other
antipseudomonal agents (Poudyal, et al., 2008).
Polymyxins are cationic polypeptides that contains a cyclic heptapeptide
possessing a tripeptide side chain acylated at the N terminus by a fatty acid tail (Falagas
et al., 2010; Li et al., 2006) (Figure 9).

Figure 9: Structures of colistin A and B, colistimethate A and B, and polymyxin B1
and B2 (Poirel et al., 2017).
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The intrinsic toxicity of colistin may be due to the hydrophobic properties of
the N-terminal fatty acyl segment, which also play a significant role for its
antimicrobial activity, and also by positions 6 and 7, which are very important (Brink
et al., 2014; Gallardo-Godoy et al., 2016). Colistin and polymyxin B are different by
just a single amino acid in the peptide ring (Figure 9) (Nation et al., 2014). While the
polymyxin B is administered directly as an active antibiotic, the colistin must be
administered as an inactive prodrug, colistin methanesulfonate (colistimethate [CMS])
(Nation et al., 2014).
The cationic polymyxins bind to the anionic outer membrane of Gram-negative
bacteria and destabilize the lipopolysaccharide (LPS) increasing the permeability of
the bacterial membrane, leading to outflow of the cytoplasmic content and eventually
cell death (Li et al., 2006; Falagas and Kasiakou, 2005). They may also have a direct
destabilizing effect in the inner membrane (Li et al., 2005) and also inhibit vital,
membrane bound respiratory enzymes (inhibition of type II NADH-quinone
oxidoreductases [NDH-2]) (Deris et al., 2013).
1.4.7.1 Resistance to polymyxins
The most common way of acquiring resistance to polymyxins is the alteration
of the LPS via cationic substitution that prevents the binding of the cationic drug
(Poirel et al., 2017; Velkov et al., 2010). This can be achieved by mutations in several
chromosomal genes that are part of the complex system responsible for the synthesis
of LPS (Fern´andez et al., 2013; Loutet et al., 2011). The most common polymyxin
resistance mechanism in bacteria is due to the shielding of phosphates on lipid A with
positively charged groups, such as phosphoethanolamine (pEtN) and L-4aminoarabinose (L-Ara4N) (Fern´andez et al., 2012; Breazeale et al., 2005). The
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complex pathways are regulated at multiple levels including the PhoP-PhoQ
regulatory system encoded by phoP locus (Figure 10).

Figure 10: Regulation pathways of LPS modifications in Klebsiella pneumoniae
(Poirel et al., 2017)

Recently, a plasmid-mediated colistin resistance gene, mcr (mobile colistin
resistance) was discovered first for E. coli and K. pneumoniae isolates recovered in
China between 2011 and 2014 (Liu et al., 2016). The overall, production of MCR-1
in E. coli leads to an increase of the MICs of polymyxins. As a result, without any
additional resistance mechanisms, the expression of MCR-1 is enough to confer
resistance to colistin in E. coli and other enterobacterial species (Poirel et al., 2017).
Till date, several variants of this gene (mcr-1 till mcr-8) have been identified.
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1.5 Aims and objectives
Long Term Aims
o To obtain the very first insight into the distribution of various types of
Klebsiella pneumoniae causing blood-stream infections in the UAE

Specific Objectives
o To establish the antimicrobial susceptibility of K. pneumoniae causing
bloodstream infections
o To assess the rate of and characterize Carbapenem Resistant K. pneumoniae
(CRKP)
o To study the rate of hypervirulent strains among bloodstream causing K.
pneumoniae (hvKP)
o To characterise these strains regarding their clonal types and virulence markers
To study the overlap between CRKP and hvKP isolates
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Chapter 2: Material and Methods
2.1 Bacterial strains
A total of 125 non-repeat K. pneumoniae bloodstream isolates were collected
in a two-year period, from January 2014 to December 2015, in Tawam Hospital
(Microbiology Department), a tertiary care hospital in Al Ain City, United Arab
Emirates (UAE). Duplicate isolates from the same patient were excluded and only the
first isolate from each case was included. Initially, the strains were speciated using the
standard microbiological procedure, i.e. VITEK® 2 ID-GN (BioMérieux, France).
Isolates were stored in duplicates in Tryptic Soy Broth (TSB, Mast) containing 10%
glycerol (Univar) at -80°C freezers. Prior each experiment strains were revived on
Tryptic Soy Agar (TSA, Mast) and incubated for 24 h at 37°C.
2.2 Antibiotic susceptibility testing
For each pure isolate, the antimicrobial sensitivity testing was performed by
disc diffusion technique as described in the guidelines of the Clinical and Laboratory
Standard Institute (CLSI, 2015). All stored K. pneumoniae isolates were freshly
cultured on Tryptic-soy agar (TSA) plates. From the cultures, 0.5 McFarland density
suspension was made in in sterile 1xPBS and this was spread onto ready-made
Mueller-Hinton agar (MHA) plates (Pangulf Lab Solution) using a sterile cotton
applicator swab (Citoswab, China) to provide semi-confluent growth. Antibiotic disks
(MAST) were applied using antibiotic dispenser (MAST), seven discs per a 90 mm
dish. All plates were incubated at 37°C for 18 h. Diameters of the zone of inhibition
were measured with a caliper. The following antibiotics were used: Amikacin (AK),
Ampicillin (AP), Amoxicillin-clavulanic acid (AUG), Aztreonam (AZT), Ceftazidime
(CAZ), Chloramphenicol (CHL), Ciprofloxacin (CIP), Cefpodoxime (CPD),
Cefotaxime (CTX), Doxycycline (DXT), Ertapenem (ERT), Fosfomycin (FOS),
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Cefoxitin (FOX), Gentamicin (GN), Imipenem (IMP), Meropenem (MEM), Nalidixic
acid (NA), Piperacillin-tazobactam (PTZ), Trimethoprim-sulphamethoxazole (SXT),
Tetracycline (T) and Tobramycin (TOB).
For quantitative assay the broth microdilution assay was used. The quantitative
susceptibility test was established against colistin (COL) only. Colistin was serially
diluted in 100 µl volume of Muller Hinton Broth (OXOID) in 96 well microplates
(Sarstedt, Germany) and inoculated by a Multipoint inoculator (MAST) to give a final
concentration of 5 x 105 colony forming units (CFU)/ml. After 18 hours of incubation
at 37°C the growth was visually assessed and the Minimum Inhibitory Concentration
of the drug (MIC) was determined as the lowest concentration preventing visible
growth of the organism tested.
Escherichia coli ATCC 25922 was used as control strain in all susceptibility
testing, and E. coli ABC149, an mcr-1 positive isolate with colistin MIC of 4mg/L was
additionally used in the colistin susceptibility testing.
Strains were considered to be multi-drug resistant if resistant to three or more
classes of drugs (Magiorakos et al., 2012).
2.3 Strategy for screening for, and characterization of hypervirulent Klebsiella
pneumoniae
All strains were screened by PCR for the presence of the iucA (Russo et al.,
2014) and rmpA (Brisse et al., 2009) genes. Those positive for iucA were also tested
for rmpA2 (Yu et al., 2015). A strain was considered to be hypervirulent if positive for
iucA and for rmpA and/or rmpA2. The capsule type (Brisse et al. 2009, Turton et al.,
2010) and the MLST (Diancourt et al., 2005) of the hvKP strains was also determined.
hvKP and cKP strains were compared in terms of the frequency of the presence of
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various siderophore genes, namely kfuBC (Brisse et al., 2009), enterobactin (entB),
salmochelin (iroB), Yersiniabactin (irp2) and aerobacting (iucA) (Russo et al., 2014)
and their positivity in string test (Patel et al., 2014; Martin and Bachman, 2018).
2.4 Extraction of bacterial genomic DNA for PCR
Three to five colonies of isolates grown overnight on TSA plates were picked
by toothpick and suspended into two 200 μl aliquots of sterile distilled water in
Eppendorf tubes. The tubes were incubated for 10 minutes at 99°C on a thermo-block
(Eppendorf). They were centrifuged for 10 minutes at 14,800 rpm; the supernatant
was collected without touching the pellet, combined in a new autoclaved Eppendorf
tube and kept at 4°C. This material was used for most experiments as the DNA target.
For selected isolates, DNA was extracted using the QIAamp DNA Mini Kit (Qiagen)
according to the manufacturers’ instruction.
2.5 Polymerase Chain Reaction (PCR)
All PCR reactions were performed on Applied Biosystems 2700 and 2720
thermocyclers. In all reactions E. coli J53RAZ genomic DNA and ultra-pure distilled
water were used as negative controls. All positive reactions first obtained were
confirmed by direct sequencing. The genes targeted, the primers and parameters used
in different PCR reactions with respective references are listed in Table 9. PCR
reactions were performed for 30-40 cycles at various annealing temperatures
depending upon the melting temperature of the primer set used. Amplicons were
analyzed on 1-2% agarose gels in the presence of ethidium bromide. Gels were
photographed and scanned using the Biometra gel documentation system (Biometra,
Gottingen, Germany). To assess the molecular mass of the amplicons Gene Ruler 100
bp DNA ladder (Fermentas) standards were run on each gel.

Table 9: Primers used in the study

Gene Targeted

Sequences
(5’- 3’)

Primers

PCR Product Size

Initial Denaturation

543bp

5’ at 94°C

Cycle

Final
Extension

Reference
s

10’at 72°C

(Cao et al.,
2002)

Detection of selected beta-lactamase genes
MA-1
MA-2

blaOXA-48-like

OXA-F
OXA-R

GCGTGGTTAAGGATGAACAC
CATCAAGTTCAACCCAACCG

438bp

5’ at 94°C

40X (30”at 94°C, 40”
at 52°C, 50” at 72°C)

10’at 72°C

(Poirel et
al., 2011)

blaKPC

KPC-F
KPC-R

CGTCTAGTTCTGCTGTCTTG
CTTGTCATCCTTGTTAGGCG

798bp

5’ at 94°C

40X (30”at 94°C, 40”
at 52°C, 50” at 72°C)

10’at 72°C

(Poirel et
al., 2011)

blaVIM

VIM-F
VIM-R

GATGGTGTTTGGTCGCATA
CGAATGCGCAGCACCAG

390bp

5’at 94°C

40X (30”at 94°C, 40”
at 52°C, 50” at 72°C)

10’at 72°C

(Poirel et
al., 2011)

blaIMP

IMP-F
IMP-R

GGAATAGAGTGGCTTAAYTCTC
GGTTTAAYAAAACAACCACC

232bp

5’ at 94°C

40X (30”at 94°C, 40”
at 52°C, 50” at 72°C)

10’at 72°C

(Poirel et
al., 2011)

TGCCGAGCGACTTGGCCTTG
ACCGATGACCAGACCGCCCA

379bp

5’at 94°C

30X (30”at 94°C, 30”
at 60°C, 60” at 72°C)

7’ at 72°C

(Ghazawi
et al.,
2012)

blaNDM

NDM1-Fo
NDM1-Re

SCS ATG TGC AGY ACC AGT AA
CCG CRA TAT GRT TGG TGG TG

30X (30” at 94°C,
30” at 55°C and 60”
at 72°C)

blaCTX-M
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Table 9: Primers used in the study (continued)
Gene Targeted

Sequences
(5’- 3’)

Primers

PCR Product Size

Initial Denaturation

Cycle

Final
Extension

Reference
s

40 X (15” at 94°C,
30” at 58°C, and 1’ at
72°C)

10’at 72°C

(Fritsche
et al.,
2008)

Detection of aminoglycoside methyltransferase genes
armA
rmtA
rmtB
rmtC
rmtD
rmtE

armA-f
armA-r
rmtA-f
rmtA-r
rmtB-f
rmtB-r
rmtC-f
rmtC-r
rmtD-f
rmtD-r

TATGGGGGTCTTACTATTCTGCCTAT
TCTTCCATTCCCTTCTCCTTT
CTAGCGTCCATCCTTTCCTC
TTTGCTTCCATGCCCTTGCC
TCAACGATGCCCTCACCTC
GCAGGGCAAAGGTAAAATCC
GCCAAAGTACTCACAAGTGG
CTCAGATCTGACCCAACAAG
CTGTTTGAAGCCAGCGGAACGC
GCGCCTCCATCCATTCGGAATAG

rmtE-f
rmtE-r

ATGAATATTGATGAAATGGTTGC
TGATTGATTTCCTCCGTTTTTG

514 bp
635 bp
459 bp

5’at 94°C

752 bp
376 bp
818 bp
5’at 94°C

rmtF

rmtF-f
rmtF-r

GCGATACAGAAAACCGAAGG
ACCAGTCGGCATAGTGCTTT

589 bp

35 X (30” at 94°C,
60” at 55°C, and 1’ at
72°C)

10’at 72°C

(Davis et
al., 2010)
(Hidalgo
et al.,
2013)
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Table 9: Primers used in the study (continued)
Gene Targeted

Primers

Sequences
(5’- 3’)

PCR Product Size

Final
Extension

Initial Denaturation

Cycle

35X (60” at 94°C,
60” at 50°C and 60”
at 72°C)

10’at 72°C

35X (60” at 94°C,
60” at 60°C and 60”
at 72°C)

10’at 72°C

Reference
s

Klebsiella pneumoniae MLST

rpoB

VIC3
VIC2

GGC GAA ATG GCW GAG AAC CA
GAG TCT TCG AAG TTG TAA CC

501 bp

5’at 94°C

gapA

gapA173
gapA181

TGA AAT ATG ACT CCA CTC ACG G
CTT CAG AAG CGG CTT TGA TGG CTT

450 bp

5’at 94°C

mdh

mdh130
mdh867

CCC AAC TCG CTT CAG GTT CAG
CCG TTT TTC CCC AGC AGC AG

477 bp

pgi

pgi1F
pgi1R

GAG AAA AAC CTG CCT GTA CTG CTG
GC
CGC GCC ACG CTT TAT AGC GGT TAA T

432 bp

ACC TAC CGC AAC ACC GAC TTC TTC
GG
TGA TCA GAA CTG GTA GGT GAT

420 bp

infB1F
infB1R

CTC GCT GCT GGA CTA TAT TCG
CGC TTT CAG CTC AAG AAC TTC

318 bp

tonB1F
tonB2R

CTT TAT ACC TCG GTA CAT CAG GTT
ATT CGC CGG CTG RGC RGA GAG

phoE

phoE604.1
phoE604.2

(Diancourt
et al.,
2005)

5’at 94°C

35X (60” at 94°C,
60” at 50°C and 60”
at 72°C)

10’at 72°C

infB

tonB

414 bp

5’at 94°C

35X (60” at 94°C,
60” at 45°C and 60”
at 72°C)

10’at 72°C

(Diancourt
et al.,
2005)
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Table 9: Primers used in the study (continued)
Gene Targeted

Primers

Sequences
(5’- 3’)

PCR Product Size

Initial Denaturation

Cycle

Final
Extension

Reference
s

7’at 72°C

(Lewis et
al., 2009)

Detection of Klebsiella pneumoniae virulence factor genes
magA
rmpA
kfuBC
Capsule type K2
Capsule type K5
Capsule type K54
Capsule type K57
Capsule type K20

mag A-F
mag A-R
rmpA-F
rmpA-R
kfuB-F1179
kfuC-R649
K2wzy-F1
K2wzy-R1
K5wzxF360
K5wzxR639
wzxK54F
wzxK54R
wzyK57F
wzyK57R
wzyK20F
wzyK20R

GGT GCT CTT TAC ATC ATT GC
GCA ATG GCC ATT TGC GTT AG
ACT GGG CTA CCT CTG CTT CA
CTT GCA TGA GCC ATC TTT CA
GAA GTG ACG CTG TTT CTG GC
TTT CGT GTG GCC AGT GAC TC
GACCCGATATTCATACTTGACAGAG
CCTGAAGTAAAATCGTAAATAGATGGC
TGGTAGTGATGCTCGCGA
CCTGAACCCACCCCAATC
CATTAGCTCAGTGGTTGGCT
GCTTGACAAACACCATAGCAG
CTCAGGGCTAGAAGTGTCAT
CACTAACCCAGAAAGTCGAG
CGGTGCTACAGTGCATCATT
GTTATACGATGCTCAGTCGC

1280 bp
535 bp

5’at 94°C

35X (30” at 94°C,
60” at 50°C and 60”
at 72°C)

797 bp
641 bp
280 bp

5’at 94°C

35X (30” at 94°C,
90” at 58°C and 90”
at 72°C)

10’at 72°C
(Turton et
al., 2010)

881 bp
1037 bp
5’at 94°C
741 bp

35X (30” at 94°C,
90” at 58°C and 90”
at 72°C)

10’at 72°C

(Turton et
al., 2010)
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Table 9: Primers used in the study (continued)
Gene Targeted

Enterobactin
(entB)

Salmochelin
(iroB)

Yersiniabactin
(irp2)

Primers

Sequences
(5’- 3’)

PCR Product Size

entB plus
entB minus

GATGAAGACGATACCGTGC
ACCGAATCCAGACCGTAGTC

388bp

iroB plus
iroB minus

ATCTCATCATCTACCCTCCGCTC
GGTTCGCCGTCGTTTTCAA

234 bp

Initial Denaturation

Cycle

Final
Extension

5’at 94°C

35X (30” at 94°C,
30” at 56°C and 60”
at 72°C)

7’at 72°C

Reference
s

(Russo et
al., 2014)

irp2 plus
irp2 minus

GCTACAATGGGACAGCAACGAC
GCAGAGCGATACGGAAAATGC

Aerobactin
(iucA)

iucA plus
iucA minus

AATCAATGGCTATTCCCGCTG
CGCTTCACTTCTTTCACTGACAGG

340 bp

5’at 94°C

rmpA2

rmpA2-F
rmpA2-R

TGTGCAATAAGGATGTTACATTAGT
TTTGATGTGCACCATTTTTCA

609 bp

5’at 94°C

229bp

35X (30” at 94°C,
30” at 58°C and 120”
at 72°C)

35X (30” at 94°C,
30” at 55°C and 60”
at 72°C)

10’at 72°C

10’at 72°C

(Yu et al.,
2015)
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2.6 String test
The string test was conducted to check the hypermucoviscosity of Klebsiella
pneumoniae colonies. The outcome result was defined as positive when an inoculation
loop was able to generate a viscous string test of ≥5 mm in length from a colony on a
blood agar plate after overnight incubation (Patel et al., 2014; Martin and Bachman,
2018), meanwhile, a negative string test was assigned when the string was less than 5
mm in length or no string was formed at all.
2.7 Pulsed Field Gel Electrophoresis (PFGE)
PFGE was performed according to Gautom. Briefly, bacterial strains grown
on TSA plates were suspended in 2ml of cell suspension buffer (100 mM Tris, 100
mM EDTA, pH8.0) up to a density of 3 McFarland unit and suspensions were kept on
ice. Simultaneously, 1% plug (low melting point) agarose (Sigma) was melted in 1%
SDS in TE buffer (10mM Tris:1mM EDTA pH8.0) and kept at 54°C. 500 μl bacterial
suspensions, 25 μl of proteinase K (Invitrogen) (20 mg/ml) and 525 μl of 1% plug
agarose were combined, mixed carefully, quickly transferred into 1 ml syringes and
kept for 15-30 minutes at room temperature to allow the solidification of the agarose.
Aliquots of 5 ml cell lysis buffer (50 mM Tris: 50 mM EDTA pH 8.0, 1% Sarkosyl)
and 25 μl proteinase K 20 mg/mL were distributed into 50 ml tubes and 1mm thick
slices of agarose plugs were directly cut into them. They were incubated for 2 hours
at 50°C in a shaking water bath (200 rpm). Subsequently, the plugs were washed twice
with 10 ml of preheated sterile MilliQ water for 20 minutes in a 50°C shaker water
bath. Plugs were washed four times each for 20 minutes with 10 ml of preheated TE
buffer. Finally, plugs were stored in 5 ml of fresh TE buffer at 4°C.
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Genomic DNA within the plugs were digested overnight at 37°C in a 100 μl
restriction mixture made of 10 μl of NE buffer 4 (New England Biolabs), 1 μl of BSA
(New England Biolabs), 30 U (1.5 μl) of XbaI enzyme (New England Biolabs) and
87.5 μl of sterile distilled water. Following digestion, the restriction mixtures were
removed, and the plugs were incubated in 250 μl of 0.5X TBE buffer for 30 minutes
at room temperature. Subsequently, plugs were inserted into wells of 1.4% of agarose
gel (Pulse Field Running Agarose A2929, Sigma) prepared in 0.5xTBE buffer each
gel contained Salmonella Braenderup strain H9812 as references standard for PFGE
loaded on three wells: two sides and a middle one. Gels were run in CHEF Mapper
(Biorad) electrophoresis chamber in 0.5X TBE buffer pre-chilled to 14°C. The running
program consisted of 26 hours run at 6 V/cm with 120 angle and an initial switch time
of 2.2 seconds and a final switch time of 54.2 seconds with linear ramp.
Gels were stained with ethidium bromide for 20 minutes, followed by destaining in MilliQ water. Bands were detected and photographed under UV light in a
Biometra gel documentation system. Gel pictures were stored as .tif files for further
analysis. The GelCompare II software (Applied Maths, Sint-Martens-Latem, Belgium)
was used to analyze the banding patterns. The Unweighted Pair Group Method with
Arithmetic Mean (UPGMA) tree graphically showing the level of relatedness between
the isolates was created based on the Dice similarity coefficient (SD) (with a 1.5%
position tolerance). For a routine analysis, strains showing patterns with SD ≥ 80%
were arbitrarily considered to represent a pulsotype.
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2.8 Multi-locus Sequence Typing (MLST)
In order to study the relatedness of K. pneumoniae strains, their genomic DNA
were typed by MLST method based on the protocol described by (Diancourt et al.,
2005) The seven housekeeping genes of seven K. pneumoniae (ropB, gapA, mdh, pgi,
phoE, infB, tonB) were amplified by the primers shown in Table 9 K. pneumoniae
isolates were assigned to sequence types using the tools onto the following webpage
(https://bigsdb.pasteur.fr/klebsiella/klebsiella.html). All hvKP strains were subjected
to MLST. For carbapenem resistant K. pneumoniae strains, if isolates formed a PFGE
cluster with >4 members, selected members of the cluster were investigated by MLST.
For this purpose, PFGE subtypes were assigned to each isolate exhibiting >90% PFGE
pattern similarity, and at least one isolate from each subtype was MLSTed.
2.9 Sequencing
PCR products were purified by PCR purification kit (Promega) prior to
sequencing. Sequencing was done using the Big Dye Cycle Terminator V.3.1 (Applied
Biosystems) according to the manufacturer's instructions. The samples were
sequenced in both directions using the 3130X Genetic Analyzer (Applied Biosystems).
Sequences

were

analyzed

using

the

MEGA5

(http://www.megasoftware.net/mega5/mega.html) and the Clone Manager v9 (Sci-Ed
software) software.
2.10 Plasmid electrophoresis and localization of the rmpA gene by hybridization
Plasmids were isolated of the rmpA positive isolates by the alkaline lysis
method of Kado and Liu (1981). Briefly, bacterial cells were collected from overnight
culture on TSA plates, and suspended in 250µl of lysing solution (3%SDS, 50 µM
Tris, pH 12.56-12.58). The suspensions were incubated in a thermoblock at 60°C for
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45 minutes, with gentle mixing every 15 minutes, followed by addition of 250 µl of
phenol-chloroform (1:1) and centrifugation at 13000 rpm for 15 minutes. About 100
µl of the top aqueous layer was transferred to another tube containing 5 µl loading dye.
Thirty µl of these samples were loaded in 0.8% agarose gel and subjected to
electrophoresis at 130 V for 4 hours. Gels were stained with ethidium bromide for 20
minutes followed by, de-staining with distilled water for 10 minutes. Rulers were
placed around the gel, then photographed to help locate the bands using a gel
documentation system (Biometra, Germany). For plasmid size control, E. coli 39R861
(Threlfall, Rowe, Ferguson, & Ward, 1986) were used. The gel was then depurinated
in 0.25 M HCl, then denatured in 0.5 M NaOH, 1 M NaCl, and lastly neutralized in 1
M Tris, 0.6 M NaCl. All steps were repeated twice for 15 minutes, with gentle
agitation, at room temperature; with the gels being rinsed with distilled water between
the steps.
The gel was transferred to Hybond N+ nylon membrane using capillary action;
with overnight soaking in 20XSSC (saline-sodium citrate). The following day,
membranes were cross-linked using UV at 70 000 microjoules. Hybridization was
done using the DIG DNA detection kit (Roche, Germany). rmpA probe previously
labelled with the same kit was used. The nylon membrane was incubated in
hybridization buffer, at hybridization temperatures for 30 minutes as a
prehybridization step, after which the hybridization buffer containing the probe was
added, incubated overnight at the hybridization temperature. Hybridization
temperature was calculated based on the size and the GC ratio of the probe using the
formula given by the manufacturer. On the next day, membranes were washed twice
with 2XSSC/1%SDS for 5 minutes at room temperature, followed by washing twice
in 0.1XSSC/1%SDS for 15 minutes at 68°C. Membranes were then rinsed in washing
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buffer at room temperature incubated in blocking solution for 30 minutes, followed by
incubation in antibody solution for 30 minutes. After that, membranes were washed
twice in washing buffer, and equilibrated in detection buffer. Finally, membranes were
incubated in color substrate solution, kept in the dark without shaking till the
appearance of the labelled band.
2.11 Collection of clinical data
Data on the age, gender, nationality, underlying illness, prior antibiotic
exposure of the patients were provided by Dr. Rayhan Hashmey (Tawam Hospital).
2.12 Ethical approval
The study was approved by the Al Ain Medical District Human Research
Ethics Committee (AAMD/HREC) No. 14/03 – CRD 309/14.
2.13 Statistical analysis
Categorical variables were compared by two-tailed Fisher’s test while the
unpaired, two-tailed Student’s t test was used to compare means. P value of <0.05 was
considered statistically significant.
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Chapter 3: Results

3.1 General characteristics of the group of patients
In total, 125 K. pneumoniae strains, the first such isolates were recovered from
blood samples of individual patients and were included in the study. Information on
gender, age, nationality and limited clinical data were available only for 122 patients.
The average age all patients included in the study was 45.58 ± 30.64 years and
representing ages 61 male and 61 female patients with respective average ages of 47.66
± 32.18 and 43.49 ± 29.13 years. The distribution of the strains by the patients’
nationality is shown wards, by nationality of the patients are show in Table 10.

Table 10: Distribution of isolates by the patients’ nationalities
Nationality

%

Nationality

%

Afghani

1.6

Palestinian

4.8

Bangladeshi

0.8

Saudi

0.8

Comoros Islandic

0.8

Serbian

0.8

Djiboutian

0.8

Sudanese

6.4

Egyptian

2.4

Syrian

2.4

Emirati

55.2

Yemeni

2.4

Ethiopian

0.8

No data

2.4

Philippine

1.6

Jordanian

2.4

Indian

3.2

Omani

1.6

Iraqi

2.4

Pakistani

5.6

As co-morbidities can considerably impact the type of infection acquired, the
frequencies of selected co-morbidities, specifically diabetes mellitus, haematological
malignancies and solid tumours among patients are shown in Table 11.
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Table 11: The frequency of selected co-morbidities among patients
Co-morbidities
Diabetes mellitus
Malignancy
Haematological
Solid tumour
Diabetes and malignancy
None of the above
No data

%
27.2
41.6
10.4
31.2
14.4
43.2
2.4

Previous exposure to antibiotics may select organisms with high resistance
profiles. Therefore, data were also collected on exposure to antibiotics within the
previous one months. The data are summarised in Table 12.
Table 12: Previous exposure to selected groups of antibiotics
Antibiotic exposure
Any antibiotics
None
Any non-beta-lactams, only
Any beta-lactams
3rd gen. cephalosporins
Carbapenems
No data

%
52.8
44.8
2.4
50.4
5.6
14.4
2.4

80%

Figure 11: Macro-restriction analysis of the strains with pulsed field gel electrophoresis
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3.2 Heterogeneity of the strains
First, the level of heterogeneity of the K. pneumoniae strains was established
by macro-restriction analysis via PFGE (Figure 11).
The population was rather heterogenous forming 36 distinct clusters and 18
singletons. The size of clusters is shown in Table 13.

Table 13 : Clustering of the strains by macro-restriction analysis
Size of the clusters

Number of
clusters

Singletons

18

Duplets

22

Triplets

8

Quadruplets

3

7 members

1

9 members

1

11 members

1

The analysis done if larger groups of strains also clustered in time and location.
The time and space distribution of members of the larger clusters (≥ 4) is shown in
Table 14.
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Table 14: Distribution of larger clusters in time and space
PFGE cluster

Date of isolation

Ward

31-01-2014

Surgical Unit 2

10-02-2014

Pediatric Intensive Care

11-03-2015

Medical Unit 3

27-04-2015

Pediatric Intensive Care

21-02-2014

Intensive Care Unit

22-10-2014

Special Medical Unit

01-11-2014

Intensive Care Unit

29-11-2015

Oncology Unit 1

05-03-2014

Hematology Unit 2

19-08-2014

Intensive Care Unit

21-08-2014

Intensive Care Unit

31-08-2015

Intensive Care Unit

21-03-2014

Pediatric Intensive Care

21-03-2014

Intensive Care Unit

08-04-2014

Intensive Care Unit

29-09-2014

Emergency Department

13-02-2015

Intensive Care Unit

04-07-2015

Medical Oncology

26-05-2015

Surgical Unit 1

24-01-2014

Surgical Unit 1

02-02-2014

High Dependency Unit

24-04-2014

Intensive Care Unit

22-10-2014

Pediatric Intensive Care

PF12

PF42

PF51

PF27

PF28
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Table 14: Distribution of larger clusters in time and space (continued)
PFGE cluster

PF32

Date of isolation

Ward

10-01-2015

Hematology Unit 2

22-01-2015

Intensive Care Unit

22-04-2015

Intensive Care Unit

26-05-2015

Surgical Unit 1

22-10-2015

Pediatric Intensive Care

18-08-2014*

Intensive Care Unit

04-09-2014*

Intensive Care Unit

16-09-2014*

Intensive Care Unit

18-11-2014*

Intensive Care Unit

29-03-2015*

Oncology Unit 1

21-05-2015*

Medical Unit 3

08-06-2015*

Oncology Unit 1

15-08-2015

Special Medical Unit 3

02-09-2015*

Intensive Care Unit

16-11-2015*

Special Medical Unit 3

10-12-2015*

Intensive Care Unit

* Strains marked are iucA positive, but were rmpA/A2 negative isolates, see later

While limited clustering in time and space (e.g. PF32 in the Intensive Care Unit
within a few weeks-times in 2014) did occur, no single locus explosive outbreak was
indicated by the analysis.
This observation was further supported by performing MLST of selected
members of PFGE clusters with >4 member. The sequence type (ST) of isolates
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exhibiting <90% PFGE pattern similarity is shown in Table 15. MLST also confirmed
the heterogeneity of isolates, as members of the PF27 cluster belonged to three STs,
PF28 cluster had isolates of seven various STs, and even the most uniform PF32 group
did not only have ST231 isolates but one isolates having ST34.

Table 15: Subtypes and multi-locus sequence types of isolates belonging to PF clusters with >4 members
UAEU No.
BC-15-56
BC-14-112
BC-14-288
BC-15-22
BC-14-96
BC-14-95
BC-15-70
BC-15-45
BC-14-47
BC-15-13
BC-15-106
BC-14-314
BC-14-130
BC-15-55
BC-15-61
BC-14-31
BC-14-280
BC-15-54
BC-15-43
BC-14-272
BC-15-117
BC-15-60
BC-14-237
BC-15-89
BC-15-125
BC-14-355
BC-15-85

PFGE type based
on >80%
similarity

PF27

PF28

PF32

PFGE subtype
based on >90%
similarity
PF27a
PF27a
PF27b
PF27c
PF27c
PF27c
PF27d
PF28a
PF28b
PF28c
PF28d
PF28e
PF28f
PF28f
PF28g
PF28h
PF32a
PF32a
PF32a
PF32a
PF32a
PF32a
PF32a
PF32a
PF32a
PF32b
PF32c

MLST

gapA

infB

Mdh

pgi

phoE

rpoB

tonB

NT
ST29
ST29
NT
ST714
ST714
ST711
ST3550
ST1770
ST23
ST334
ST35
ST23
ST3549
ST2433
ST23
ST231
ST231
ST231
NT
NT
NT
NT
NT
NT
ST231
ST34

NT
2
2
NT
2
2
2
2
18
2
18
2
2
2
2
2
2
2
2
NT
NT
NT
NT
NT
NT
2
2

NT
3
3
NT
3
3
61
1
22
1
22
1
1
1
106
1
6
6
6
NT
NT
NT
NT
NT
NT
6
3

NT
2
2
NT
2
2
2
1
18
1
18
2
1
1
4
1
1
1
1
NT
NT
NT
NT
NT
NT
1
6

NT
2
2
NT
2
2
2
224
63
1
22
1
1
1
158
1
3
3
3
NT
NT
NT
NT
NT
NT
3
1

NT
6
6
NT
6
6
6
9
11
9
25
10
9
9
248
9
26
26
26
NT
NT
NT
NT
NT
NT
26
9

NT
4
4
NT
4
4
4
4
13
4
37
1
4
191
1
4
1
1
1
NT
NT
NT
NT
NT
NT
1
7

NT
4
4
NT
160
160
4
12
179
12
51
19
12
12
19
12
77
77
77
NT
NT
NT
NT
NT
NT
77
4
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3.3 Antibiotic resistance of the isolates
The susceptibility rates to specific antibiotics are shown in Table 16.
Table 16: Susceptibility rates of the isolates
Antibiotics

%
Susceptible

Amoxicillin-clavulanate

67.2

Cefoxitin

81.6

Piperacillin–tazobactam

62.4

Ceftazidime

69.6

Ceftriaxone

65.6

Cefotaxime

65.6

Aztreonam

72.0

Ertapenem

88.0

Imipenem

88.8

Meropenem

88.8

Amikacin

86.4

Gentamicin

77.6

Tobramycin

72.8

Ciprofloxacin

77.6

Trimethoprim–sulfamethoxazole

65.6

Doxycycline

77.6

Chloramphenicol

77.6

Fosfomycin
Colistin

100.0
96.8

Based on these figures, 47 isolates (37.6%) were multi-drug resistant, i.e.
resistant to three or more classes of antibiotics (Magiorakos et al., 2012). Those
patients who received antibiotic therapy prior to the isolation of K. pneumoniae from
the blood sample were significantly more likely to harbour an MDR isolate
(P=0.0081). Other variables were not associated with having an MDR K. pneumoniae
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infection (Table 16).
Furthermore, 15 isolates (12.0%) qualified as carbapenem resistant K.
pneumoniae (CRKP), i.e. exhibiting non-susceptibility to at least one (always
including ertapenem) of the carbapenems tested. Patients from whom CRKP were
isolated were not exposed to antibiotics or to beta-lactam antibiotics more often than
other patients (P=0.0503 and 0.0986). However, they were highly significantly more
likely to receive prior carbapenem therapy (P=0.0098). No correlation between being
infected with a CRKP strain and the presence of diabetes mellitus or any malignancy
or being Emirati or non-Emirati was found either (P=1.0, 0.4059, 0.7887, respectively)
(Table 17).
Table 17: Correlation of different variables with having a multi-drug, or carbapenem
resistant K. pneumoniae (CRKP) infection
Variables

MDR (n=44)#

Non MDR (n=78)

Prior antibiotic therapy

31

35

0.0081

Malignancy

21

31

0.4478

Diabetes mellitus

11

26

0.4138

Emirati nationality

23

46

0.5688

CRKP
(n=15)

CSKP
(n=107)#

Prior antibiotic therapy

12

54

0.0503

Prior beta-lactam therapy

11

52

0.0986

Prior carbapenem therapy

6

12

0.0098

Malignancy

8

43

0.4059

Diabetes mellitus

4

30

1.0

Emirati nationality

8

61

0.7887

Variables

P

P

# n is the number of patients whose data were available
MDR: Multi-drug resistant, CRKP: Carbapenem resistant K. pneumoniae, CSKP: carbapenem
susceptible K. pneumoniae
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3.4 Susceptibility of the carbapenem resistant isolates to non-beta-lactam
antibiotics
Although the most common mechanisms causing resistance to carbapenems in
Enterobacteriaceae does not cause resistance to non-beta-lactams antibiotics, per se,
often carbapenem resistant strains exhibit non-susceptibility to several drugs of
different classes. The comparison is done for the susceptibilities of strains to such
antibiotics. As can be seen on Table 18, with the exception of fosfomycin and colistin,
CRKP strains were significantly less often susceptible than their carbapenem
susceptible, CSKP, counterparts.
Table 18: Comparative susceptibilities of carbapenem resistant (CRKP) and
carbapenem susceptible (CSKP) Klebsiella pneumoniae to non-beta-lactam
antibiotics
% Susceptible
CRKP

CSKP

Significance
(P)

6.7

98.2

< 0.0001

Gentamicin

13.3

86.4

< 0.0001

Tobramycin

0.0

82.7

< 0.0001

Ciprofloxacin

6.7

87.3

< 0.0001

Trimethoprim–
sulfamethoxazole

6.7

73.6

< 0.0001

53.3

79.1

0.0482

6.7

87.3

< 0.0001

100.0

100.0

1.0

86.7

98.2

0.0703

Antibiotics
Amikacin

Doxycycline
Chloramphenicol
Fosfomycin
Colistin
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3.5 Molecular characterization of carbapenem resistant Klebsiella pneumoniae
The mechanism of carbapenem resistance was determined by subjecting the
isolates to PCR targeting the most common carbapenemase enzymes. The results are
shown in Table 19. All strains produced at least one carbapenemase, with the exception
of one that expressed both NDM and an OXA-48-like genes.

Table 19: Distribution of carbapenemase genes in CRKP isolates
Carbapenemase produced

%

blaOXA-232

73.3

blaOXA-162

6.7

blaNDM-1

6.7

blaNDM-1 + blaOXA-232

6.7

blaVIM

6.7

Eleven (73.3%) of the CRKP strains carried a blaCTX-M gene, while the same
figure among the CSKP isolates was 20.1% (P=0.0001).
As with the exception of two CRKP strains, all isolates exhibited nonsusceptibility to all the aminoglycosides tested. Exploring the presence of 16S
methylase genes and with exception of the above mentioned two isolates, all CRKP
strains carried such genes. Actually, 10 (69.1%) carried rmtF, while 3 (20%) carried
armA. In none of the CSKP isolates could detect any 16S methylase genes, irrespective
of the spectrum of their aminoglycoside resistance.
No mobile colistin resistance genes were detected in any of the colistin resistant
strains.
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The macrorestriction analysis of the CRKP strains revealed that beyond 5
singletons, 10 of them belonged to a single cluster, PF32. The MLST analysis revealed
that two singletons belonged to ST14, further 3 belonged to ST23, ST307 and ST70,
respectively. The 10 member-strong cluster was made up by ST231 isolates, all
expressing the blaOXA-232, rmtF genotype.
3.6 Screening for hypervirulent strains
All strains were screened for the presence of rmpA and iucA genes and those
carrying iucA were also tested for rmpA2. Strains carrying iucA and rmpA and/or
rmpA2 were considered hypervirulent. Of the 125 strains tested, only 13 (10.4%)
fulfilled the criteria.
3.7 Characterization of hypervirulent strains
3.7.1 Molecular typing of hypervirulent strains
In order to assess more subtle relationships between hvKP strains their PFGE
patterns were reanalysed without the effect of the large number of cKP outliers. As
seen in Figure 12, 6 strains formed a large cluster (previously assigned to PFGE
patterns PF28 in Figure 11) while two strains (previously belonging to PF27) formed
a pair. The remaining hvKP strains were singletons.
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Figure 12: Macro-restriction patterns of the hvKP strains-dashed line indicates 80%
similarity

MLST analysis of the strains revealed that the 6 isolates clustering together all
belonged to ST23 or CC23, i.e. single locus variants (SLV) of ST23, while the duplets
were ST714 (Table 20).
Table 20: Sequence types, date and location of isolation of hvKP strains
Strains
BC-15-61
BC-14-130
BC-14-31
BC-15-13
BC-15-55
BC-15-45
BC-14-197
BC-15-34
BC-15-51
BC-14-298
BC-14-95
BC-14-96
BC-14-79

Sequence type
ST23
ST23
ST23
ST23
ST3549-CC23
ST3550-CC23
ST36
ST380
ST380
ST65
ST714
ST714
ST86

Date of isolation
16-06-2015
24-04-2014
24-01-2014
22-01-2015
26-05-2015
22-04-2015
05-07-2014
09-03-2015
11-05-2015
08-10-2014
21-03-2014
21-03-2014
11-03-2014

Ward
Special Medical Unit 3
Intensive Care Unit
Surgical Unit 1
Intensive Care Unit
Surgical Unit 1
Intensive Care Unit
Intensive Care Unit
Emergency Department
Oncology Unit 1
VIP Unit
Intensive Care Unit
Pediatric Intensive Care Unit
Intensive Care Unit

As can be seen in Table 20, strains were not recovered from an explosive
outbreak, but the distribution of isolation times and location are rather heterogenous.
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3.7.2 The capsule type, string test positivity and the presence of siderophore genes
The capsule type, positivity in string test and the presence of various iron
acquisition genes are shown in Table 21.
Table 21: Capsule type, string test and iron acquisition genes of hvKP strains
Capsule
type

String
test

ST23

K1

pos

iucA, kfuBC, entB, iroB, irp2

BC-14-130 ST23

K1

pos

iucA, kfuBC, entB, iroB, irp2

BC-14-31

ST23

K1

pos

iucA, kfuBC, entB, iroB, irp2

BC-15-13

ST23

K1

pos

iucA, kfuBC, entB, iroB, irp2

BC-15-55

ST3549CC23

K1

pos

iucA, kfuBC, entB, iroB, irp2

BC-15-45

ST3550CC23

K1

pos

iucA, kfuBC, entB, iroB, irp2

BC-14-197 ST36

ND

neg

iucA, entB, iroB, irp2

BC-15-34

ST380

K2

pos

iucA, kfuBC, entB, iroB, irp2

BC-15-51

ST380

K2

neg

iucA, kfuBC, entB, iroB, irp2

BC-14-298 ST65

K2

pos

iucA, entB, iroB, irp2

BC-14-95

ST714

ND

neg

iucA, entB, iroB, irp2

BC-14-96

ST714

ND

neg

iucA, entB, iroB, irp2

BC-14-79

ST86

K2

neg

iucA, entB, iroB, irp2

Strain
BC-15-61

Sequence
type

Siderophore genes

The string test was uniformly positive in all K1 capsule type strains and yielded
varying results with the K2 isolates, but was negative with the other strains. The most
common siderophore systems were present in all isolates, and the majority of them
carried the ABC transporter kfuBC genes, as well.
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The comparative respective figures found in cKP strains are shown in Table
22. While hvKP isolates carried as many as 4.53 ± 0.66 iron acquisition related genes
per strains, the same figure among cKP was 1.94 ± 0.92, only. With the exception of
enterobactin gene entB, present in all strains, all other iron acquisition related genes
were significantly more common among hvKP isolates. Nevertheless, the only gene
clearly distinguishing between the two group of strains was iroB, part of the
salmochelin siderophore system.

Table 22: Frequency of iron acquisition system genes and string test positivity
among cKP and hvKP strains
% positivity
Gene / Feature

Significance (P)
cKP

hvKP

iucA

9.8

100.0

<0.0001

kfuBC

30.4

61.5

0.0322

entB

100.0

100.0

1.0

iroB

0.0

100.0

<0.0001

irp2

54.5

100.0

0.0008

3.6

61.5

<0.0001

Genes

Feature
String test

It was noteworthy that none of the String test positive cKP strains carried any
iron acquisition related genes beyond the omni-present entB.
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3.7.3 The location of the rmpA gene
Studying the location of the rmpA gene in the hvKP isolates. Hybridizing the
plasmid electrophoresis gel of the strains with a rmpA specific probe revealed that in
all isolates the gene was located on plasmids of varying size, but all were large (>150
kb) in size (Figure 13).

154 kb

Figure 13: Localization of the rmpA gene 39R861: Plasmid molecular weight
standard

3.7.4 Antimicrobial susceptibility of hypervirulent strains
Analysing the antimicrobial susceptibility of hvKP strains revealed that, in
general, they were highly susceptible (Table 23). There was one single exception, a
carbapenem resistant, i.e. CRKP, in which the highly virulent character was combined
with an extensive resistance pattern. It was noteworthy, that despite its broad range of
non-susceptibility (AMC, PTZ, FOX, CPD, CAZ, CTX, IMI, MEM, ERT, SXT, AK,
TOB, DOX), this strain (BC-15-13) still exhibited susceptibility to colistin. On the
other hand, one isolates (BC-15-34) while universally susceptible, was resistant to the
polymyxin.
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The CR hvKP strain carried a blaVIM carbapenemase gene, which represented
a new allele, VIM-55 (GenBank MG552720).

Table 23: Rate of susceptibilities of hvKP strains
Antibiotics

%
Susceptible

Amoxicillin-clavulanate

84.6

Cefoxitin

84.6

Piperacillin–tazobactam

61.5

Ceftazidime

84.6

Ceftriaxone

84.6

Cefotaxime

84.6

Aztreonam

92.3

Ertapenem

92.3

Imipenem

92.3

Meropenem

92.3

Amikacin

92.3

Gentamicin

100.0

Tobramycin

84.6

Ciprofloxacin

100.0

Trimethoprim–sulfamethoxazole

92.3

Doxycycline

92.3

Chloramphenicol

92.3

Fosfomycin
Colistin

100.0
92.3
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3.8 Characteristics of patients carrying hypervirulent Klebsiella pneumoniae
Patients suffering from hvKP infections were significantly more likely to have
diabetes and were significantly less likely to have received previous antibiotic therapy.
Although the frequency of being Emirati was considerably more common among
patients with cKP infections, the difference did not reach statistical significance (Table
24).
Table 24: Comparison of patients’ characteristics with cKP and hvKP infections
% positivity
Gene / Feature

Significance
(P)

cKP*

hvKP

Diabetes

22.0

76.9

0.0001

Malignancy

43.1

38.5

1.0

44.1 ± 33.45

55.6 ± 22.96

0.2116**

58.7

38.5

0.2367

Any antibiotics

57.8

23.1

0.0208

Any beta-lactams

55.0

23.1

0.0807

Carbepenems

14.7

15.4

1.0

Co-morbidities

Nationality
Age
Emirati
Antibiotic exposure

* 109 patients for whom data were available
** Student’s t test

3.9 iucA positive but rmpA/A2 negative strains
Eleven strains, while carrying the iucA gene, were rmpA/A2 negative and
hence, they did not qualify as hvKP. Nevertheless, they carried a broad panel of ironacquisition genes. The average number of such genes per strain was 3.90 ± 0.30
compared to that seen in hvKP (4.53 ± 0.66), and much higher than seen in the 101
iucA negative cKP strains (1.73 ± 0.69). With the exception of one ST502 isolate, they
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formed a single PFGE cluster (PF32) and represented ST231. These 10 strains were
all carbapenem resistant carrying a blaOXA-232 gene and the rmtF 16S methylase gene.
All of them exhibited a broad range of resistance, two of them being non-susceptible
to colistin, too.
The time and location distribution of their isolation is shown in Table 14 (the
iucA positive, but rmpA/A2 negative isolated are marked by a *).
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Chapter 4: Discussion

During the two-year-long collection period 125 cases of Klebsiella
pneumoniae bloodstream infection (BSI) were identified in our 461-bed tertiary care
hospital. As most of the literature deals with MDR K. pneumoniae bloodstream
infections, it is difficult to find general data on the incidence of K. pneumoniae BSI.
Furthermore, even if data were available it is problematic to compare the incidence in
variable clinical settings. Nevertheless, the rate of K. pneumoniae BSI during a twoyear-long period was high in our setting, if compared it to a 1420-bed tertiary-care
teaching hospital in Northern Italy, where 217 unique patient K. pneumoniae BSIs
were described during a same time-period (Girometti et al., 2014). This higher rate
could possibly be explained by the fact that a large proportion of our patients suffered
of either a solid tumour or of a haematological malignancy, and the BSI could have
been the result of a mucosal barrier injury. It is especially plausible, as it has been
shown that Klebsiella pneumoniae infections often originate from the patient’s own
intestinal microbiota (Gorrie et al., 2017). Since our study was a retrospective
investigation of K. pneumoniae isolated from bloodstream, unfortunately there is no
data on the intestinal carriage of K. pneumoniae by these 125 patients to support this
hypothesis.
Of the 125 K. pneumoniae isolates 47 (37.6%) qualified as MDR using the
European Centre for Disease Prevention and Control criteria (Magiorakos et al., 2012).
This is a slightly higher figure than the one reported recently from South Korea
(31.3%) (Kim et al., 2019), but substantially lower than the 64% reported from the
above mentioned healthcare facility in Northern Italy (Girometti et al., 2014). The nonsusceptibility to carbapenems in our collection, has not reached the Italian level of
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47%, however, it is markedly higher than the South Korean CRKP rate (12% in our
hospital vs. 3.1% in South Korea) (Girometti et al., 2014; Kim et al., 2019). It is
noteworthy that prior antibiotic therapy was linked to the isolation of MDR K.
pneumoniae. Prior carbapenem therapy, on the other hand, was significantly linked to
the isolation of a CRKP. Our findings confirm similar observations reported earlier
from multiple geographical regions (Liu et al., 2018; Park et al., 2012).
Despite the fact that K. pneumoniae, especially MDR K. pneumoniae, is prone
to spread within the hospital settings (Hendrik et al., 2015), in this study the PFGE and
MLST analysis has revealed a large variety of K. pneumoniae strains causing BSI, with
only three clusters having >4 members exhibiting >80% similar PFGE patterns (Figure
11). These results are suggestive of effective infection prevention and control program
in our hospital. On the other hand, assuming that these K. pneumoniae strains likely
originated from the patients’ own gastrointestinal tract (Gorrie et al., 2017), the
findings also underline the importance of screening for colonisation of high risk
patients.
Revealing colonisation is especially important in the lights of the relatively
high proportion of carbapenem resistant K. pneumoniae causing bloodstream
infections, with predominance of OXA-232 producing K. pneumoniae ST231 carrying
aerobactin, yersiniabactin and enterobactin siderophore genes. Carrying three or four
siderophores was associated with being more virulent in a large study comparing
virulence of K. pneumoniae (Holt et al., 2015), therefore the clonal spread of
carbapenem resistant K. pneumoniae ST231, not only multidrug resistant but also
virulent, is a serious concern. Although the K. pneumoniae ST231 clone is not
considered an international high risk clone (Navon-Venezia et al., 2017), it has been
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reported to carry blaOXA-232 and to disseminate rapidly causing outbreaks in Brunei
(Abdul Momin et al., 2017) and in India (Shankar et al., 2019). Sporadic OXA-232
producing ST231 isolate was also reported from Switzerland (Mancini et al., 2018).
As only limited time and location overlap was observed within this cluster of strains,
such isolates were either repeatedly introduced into our institution or they had a
common source yet to be revealed, but investigation of either of these hypotheses was
beyond the scope of the study.
The hypothesize is that this latter group of virulent and highly resistant isolates
could also be considered as just being one step away to become really hypervirulent,
i.e. by acquiring the plasmid-encoded rmpA/A2 genes. Only further surveillance work
encountering ST231 hvKP otherwise closely related to these isolates could prove our
assumption about the potential dangers of the evolvement of this highly resistant,
hypervirulent variety.
The other NDM and/or OXA-48-like producer isolates in the collection were
diverse: OXA-232 or NDM-1 and OXA-232 co-producer ST14, OXA-162 producer
ST307 and an NDM-1 producer ST70. The former two clonal lineages of K.
pneumoniae are recognized as important international outbreaks clones (NavonVenezia et al., 2017), and both has been described already from the UAE to produce
NDM-1 or OXA-48-like carbapenemases, or co-produce these carbapenemases. (AlBaloushi et al., 2018; Moubareck et al., 2018; Mouftah et al., 2019; Sonnevend et al.,
2015).
ST70 is not considered a high-risk epidemic clone, however it was reported to
carry blaCTX-M-type ESBL gene in Bulgaria (Markovska et al., 2017), blaKPC-2 in
Argentina and in Brazil (Jure et al., 2019; Seki et al., 2011) and recently also to harbour
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blaNDM-1 in Greece (Politi et al., 2019). In all these reports K. pneumoniae ST70
occurred sporadically, but the presence of this clone in South America, the Balkan and
now in the Gulf Region shows its capability to acquire genes coding for broad
spectrum beta-lactam hydrolysing genes including various carbapenemases.
Isolates of the other larger PFGE cluster, PF27 (Table 15) belonged to ST29,
ST711 and ST714, which are all part of the clonal complex CC29. Members of this
clonal complex were described to be ESBL (Surgers et al., 2019), or carbapenemase
producers OXA-48 (Uz Zaman et al., 2014), NDM-1 (Mukherjee et al., 2019), and
also being hypermucoviscous and hypervirulent (Turton et al., 2019). This latter
hypervirulent subtype of CC29 were reported to have K54 capsular serotype. In our
collection two K. pneumoniae ST714 isolates of this clonal group possessed rmpA/A2,
salmochelin, aerobactin and yersiniabactin, but PCR for the K54 serotype did not
detect the relevant gene, and the isolates were not hypermucoviscous by string test.
Despite of these facts, these two isolates were considered hypervirulent based on their
genotypes as suggested by Russo and Marr (2019). The hypervirulent ST714-CC29
isolates remained susceptible to 3rd generation cephalosporins, but other members of
the group with ST29 and ST711 were ESBL producers and carried the blaCTX-M gene.
Consequently, although PFGE clustered these isolates, they were rather heterogenous.
Even though, OXA-48 carbapenemase ST29 isolates were reported to cause outbreak
in the region (Zaman et al., 2014), in our collection all CC29 isolate remained
susceptible to carbapenems.
The third large PFGE cluster, PF28 also contained several isolates with
different sequence types (Table 15), further confirming the heterogeneity of our K.
pneumoniae collection. It was noteworthy though that five members of this cluster of

90
nine isolates belonged to ST23 or its single locus variants ST3549 and ST3550. These
two sequence types were novel, first reported by us. ST23, or rather the clonal complex
CC23 is considered as the prototype of hypervirulent K. pneumoniae. (Wyres et al.,
2019) Indeed, these 5 isolates of PF28 cluster harboured the rmpA/A2, salmochelin,
aerobactin and yersiniabactin genes, had K1 serotype and were phenotypically
hypermucoviscous (Table 21). In addition to these CC23 isolates, identified a further
string test positive, genotypically hypervirulent K. pneumoniae ST23 with capsular
type K1, exhibiting a slightly different PFGE profile. Of the six CC23 isolate five were
susceptible to all of the antibiotics tested, but one isolate BC-15-13 was resistant to 3rd
generation cephalosporin, carbapenem, co-trimoxazole, amikacin, tobramycin,
tetracycline and chloramphenicol. BC15-13 carried a novel VIM allele by PCR and
sequencing: VIM-55. This allele differs from VIM-19 by one amino acid, at position
229 in VIM-55 an arginine replaces the histidine found in VIM-19. Exploring the
genetic support and hydrolytic activity of this novel enzyme was beyond the scope of
my research, further ongoing studies should reveal these features. Carbapenemase
producer K. pneumoniae ST23 is a rare finding, although two members of the clone
were reported to produce OXA-48 or NDM-1 from the United Kingdom (Turton et al.,
2018) (Roulston et al., 2018). VIM-producing members of the clone were only recently
encountered in China (blaVIM-1) (Dong et al., 2019) and in Iran (blaVIM-2). (Mohammad
et al., 2018) Nevertheless, finding of an isolate, which is MDR and hypervirulent is a
most feared scenario, as such bacteria are truly “superbugs”, with a great capacity to
cause disease and at the same time being extremely difficult to treat.
Further to identifying hypervirulent K. pneumoniae of the CC23 and CC29, it
has been described here hvKP belonging to sequence types ST36, ST380, ST65 and
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ST86, all possessing rmpA on plasmid, four siderophore genes, and all but the ST36
isolate having capsular type K2 (Table 21).
K. pneumoniae ST36 has been reported to be present in several continents, is
a known hvKP causing bacteremia, and it has also been reported to produce KPC-2
from China. (Feng et al., 2018) Our ST36 isolate was non-susceptible to piperacillintazobactam, to 3rd generation cephalosporins and to monobactams, but remained
susceptible to carbapenems and non-beta-lactam antibiotics.
The predominant serotype K2 hypervirulent clones K. pneumoniae clones are
the ST65, ST86, and ST380 (Bialek-Davenet et al., 2014), and members of all of these
three clones were present and caused bloodstream infection in our institution. Isolates
belonging to these clones were susceptible to antibiotics, i.e. they were typical hvKP.
Hypervirulent K. pneumoniae infection, commonly encountered in the Pacific
Rim of Asia and in China (Paczosa and Mecsas, 2016), has only been sporadically
reported from the Gulf region. A few cases of infections caused by hypermucoviscous
K. pneumoniae were reported from Saudi Arabia (Enani and El-Khizzi, 2012) and
Oman (Basu et al., 2009), without any molecular characterization. Therefore, to the
best of our knowledge, our observation is the first in the region describing hvKP strains
causing bloodstream infections. It is noteworthy, that like the majority of cKP, the
hvKP isolates were also diverse.
In line with the earlier observations (Li et al., 2018; Russo and Marr, 2019),
patients with diabetes, and those who did not received antibiotic therapy prior to the
bloodstream infection were significantly more likely to suffer of an hvKP infection in
our setting as well. Unfortunately, although reports on hvKP infections emphasis the
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ability of such strains to cause metastatic abscesses (Russo and Marr, 2019), no clinical
information on metastatic infections, e.g. endophtalmitis, meningitis or liver abscess,
neither on the 30-day-mortality were available to us.
Defining hvKP is still a controversial issue, and the approach followed in our
study by relying only on the genomic definition is widely accepted (Li et al., 2018).
Further studies to complement our findings should confirm our, genomic definition of
hypervirulence by performing in vivo studies. However, genetically hypervirulent
isolates did not always exhibit full virulence in in vivo (Fu et al., 2019) but surmised
the virulence potential of the isolates’ as all of them caused an invasive infection, i.e.
were from the bloodstream.
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Chapter 5: Conclusions

The majority of K. pneumoniae isolated from the two-year-long study period
exhibited diverse molecular fingerprints. More than a third of the isolates were multidrug resistant, and isolation of an MDR K. pneumoniae infection was more likely if
the patient had previous exposure to antibiotics. High carbapenem resistance rate was
detected with the predominance of OXA-232 producing K. pneumoniae ST231. Over
10% of the collection was hypervirulent K. pneumoniae based on genomic definition,
i.e. the presence of plasmid-borne rmpA, salmochelin, aerobactin and yersiniabactin
genes. The hypervirulent isolates were also diverse, belonging to ST23, ST3549,
ST3550, ST36, ST380, ST65, ST714 and ST86. The presence of ST231 CRKP strains
carrying the siderophore genes otherwise characteristic to hvKP, but lacking the
rmpA/A2 gene needs further attention as, at least theoretically, the mere acquisition of
a plasmid carrying the rmpA/A2 gene could convert these highly resistant strains to
real hvKP. Diabetic patients and those who did not receive prior antibiotic therapy
were more likely to have hypervirulent K. pneumoniae infection. The majority of
hypervirulent K. pneumoniae were susceptible to antibiotics, however an ST23 isolate
was carbapenem resistant due to the production of a novel metallo-beta-lactamase,
VIM-55.
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